12th European Congress on Epileptology
11th - 15th September 2016
Congress Programme
www.epilepsyprague2016.org
CONTENTS

GENERAL INFORMATION

Committee and Welcome Messages................................................................. 4
Congress Information...................................................................................... 7
Venue Floor Plans............................................................................................ 10
Prague Transport Information......................................................................... 13

SCIENTIFIC PROGRAMME

Scientific Programme Information................................................................. 16
Scientific Programme at a Glance................................................................. 18
Sunday 11th September.................................................................................... 20
Monday 12th September................................................................................... 30
Tuesday 13th September................................................................................... 46
Wednesday 14th September............................................................................ 66
Thursday 15th September................................................................................ 90
Satellite Symposia.......................................................................................... 102

POSTERS

Posters Information......................................................................................... 108
Monday 12th September.................................................................................. 109
Tuesday 13th September.................................................................................. 131
Wednesday 14th September.......................................................................... 155

OTHER INFORMATION

Travel Bursaries............................................................................................... 180
Speaker and Chair Index............................................................................... 181
Exhibition Information.................................................................................... 196
DOWNLOAD THE FREE 12th ECE APP

Download the FREE 12th European Congress on Epileptology App now to access congress information at the touch of a button

Key App features:
- Scientific Programme
- Session Details
- Abstracts
- General Information
- Exhibition Information
- and many more...

Search: 12th ECE Prague 2016

Download the App for iPhone, iPad, Android Phone/Tablet, Kindle Fire or Windows Phone. There is FREE wifi available during the congress for all registered delegates

The Congress App is supported by:

www.epilepsyprague2016.org
WELCOME MESSAGES

WELCOME MESSAGE FROM THE CO-CHAIRS OF THE INTERNATIONAL SCIENTIFIC AND ORGANISING COMMITTEE

Dear Colleagues,

On behalf of Czech Chapter and the Commission on European affairs (CEA) of the International League Against Epilepsy (ILAE) as well as the International Scientific and Organising Committee (ISOC), it is our pleasure to welcome you to Prague for the 12th European Congress on Epileptology (ECE). In keeping up with the tradition and the reputation that the European Congress on Epileptology has for being an innovative and highly educational meeting, the 12th ECE will utilise all of the best features from recent ECEs and combine these with local Czech elements.

The ISOC has created a scientific program which we are sure will be of great interest to all, encompassing recent scientific developments and exchange of ideas and information between basic scientists, researchers and clinicians working in the field of epilepsy throughout the region.

From the many session proposals submitted by our colleagues in the region, the ISOC has chosen four main themes and selected a Chairs’ Symposium, teaching courses, ECE forums and workshops. The programme will cover many aspects of modern epileptology, bridging molecular and social levels of the disease along with basic science and everyday clinical practice.

The long and great Czech tradition in medical sciences, including Jan Marcus Marci, Jan Evangelista Purkinje and Johann Gregor Mendel, will meet with recent scientific discoveries in the magical city of Prague. This will be a unique opportunity not only to uncover the past and see the future, but also to pursue professional passions and an unrivalled opportunity to meet with colleagues, old and new.

We trust that you will enjoy the congress, as well as your stay in the beautiful city of Prague.

With kind regards,
MESSAGE FROM THE PRESIDENT OF THE ILAE

Dear Colleagues,

On behalf of the International League Against Epilepsy (ILAE), it gives me great pleasure to welcome you all to the 12th European Congress on Epileptology in the beautiful and historic city of Prague.

The International Scientific and Organising Committee has done a wonderful job in assembling a wide range of exciting scientific sessions which highlight the latest developments in understanding the mechanisms of epilepsy and state-of-the-art approaches to improve diagnosis and management. The congress will also offer a great opportunity to meet colleagues and friends from all over the world, exchange ideas, and establish fruitful collaborations.

The ILAE was established in 1909 and now has over 100 Chapters throughout the world. The ILAE Commission on European Affairs continues to promote epilepsy care, education and research across Europe, and dedicates a remarkable amount of time and effort to ensure excellence in the scientific quality of the European Congress on Epileptology.

The city of Prague is designated as a UNESCO World Heritage City and has been called “the city of a hundred spires”. It is both an ancient and modern city, renowned for its architectural and cultural richness. Throughout the centuries, Prague’s strategic position at the heart of central Europe has enabled the city to play an important role in European history. On the occasion of the 12th ECE, the city will once again become a strategic meeting point for people from many countries, with the common goal of improving the care of persons with epilepsy in Europe and beyond.

I look forward to meeting you over the coming days and trust that you will have a productive and enjoyable experience at the 12th European Congress on Epileptology and in Prague.

With best wishes,

Emilio Perucca
ILAE President

CONGRESS INFORMATION

FACILITIES TIMETABLE OVERVIEW

<table>
<thead>
<tr>
<th></th>
<th>Sunday</th>
<th>Monday</th>
<th>Tuesday-18:30</th>
<th>Wednesday</th>
<th>Thursday</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>08:00-19:00</td>
<td>07:00-17:30</td>
<td>07:00-18:30</td>
<td>07:00-18:30</td>
<td>07:00-14:00</td>
</tr>
<tr>
<td>Coffee Break</td>
<td>-</td>
<td>11:00-11:30</td>
<td>11:00-11:30</td>
<td>11:00-11:30</td>
<td>10:30-11:00</td>
</tr>
<tr>
<td>Posters</td>
<td>-</td>
<td>10:00-17:00</td>
<td>10:00-17:00</td>
<td>10:00-17:00</td>
<td>-</td>
</tr>
<tr>
<td>Exhibition</td>
<td>-</td>
<td>09:00-16:30</td>
<td>09:00-16:30</td>
<td>09:00-16:30</td>
<td>-</td>
</tr>
<tr>
<td>Cloakroom</td>
<td>08:15-20:45</td>
<td>07:15-18:15</td>
<td>07:15-19:45</td>
<td>07:15-20:00</td>
<td>07:15-13:45</td>
</tr>
<tr>
<td>Speakers’ Room</td>
<td>09:00-19:00</td>
<td>07:00-17:00</td>
<td>07:00-18:30</td>
<td>07:00-18:30</td>
<td>07:00-13:00</td>
</tr>
</tbody>
</table>

ABSTRACTS USB STICK

The abstract USB sticks are available at the BIAL exhibition booth.
Vouchers are available at the congress bag counter.

CERTIFICATES OF ATTENDANCE

Certificates of attendance may be collected from the registration area from Tuesday 13th September onwards during registration opening hours.

CLOAKROOM

The cloakroom is located in the Forum Hall Foyer on the first floor of the congress centre beside the registration area. The cloakroom is free of charge for congress participants. Opening times can be found in the Facilities Timetable Overview.

CME ACCREDITATION

The 12th European Congress on Epileptology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The 12th European Congress on Epileptology is designated for a maximum of (or ‘for up to’) 23 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMSEACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
CONGRESS APP
A free app called “12thECE, Prague 2016” is available for Apple, Windows and Android devices. Search on the app store for “12ECE”. The app provides access to all scientific sessions information such as date, times and content as well as enabling delegates to create their own personalised schedule. The congress app is supported by UCBBIOPHARMA SPRL.

COFFEE BREAKS
Coffee breaks will be served Monday to Wednesday mornings in the Exhibition Area, in the Congress Hall Foyer on the second floor of the congress centre. On Thursday, coffee breaks will be served in the Forum Hall Foyer on the second floor.

CONGRESS BAGS
Congress bags may be collected from the Registration Area.

CONGRESS SECRETARIAT
Members of the congress secretariat may be contacted at any time at the registration area. For queries arising after the congress, please contact: 12th ECE Prague 2016: Tel: +353 1 2056720 | Fax: +353 1 2056156 | Email: prague@epilepsycongress.org

EXHIBITION AREA
The exhibition area is situated in the Congress Hall Foyer on the second floor of the congress centre. Exhibition opening times are listed in the Facilities Timetable Overview.

INTERNET CENTRE
The internet centre is located on the second floor, adjacent to the exhibition and poster areas. The internet centre is supported by BIAL and Eisai.

LANGUAGE
The official language of the congress is English; please note that translation facilities are not provided.

LIABILITY AND INSURANCE
The International League Against Epilepsy (ILAE) and its agents do not accept any liability whatsoever for death, personal injury, accidents, theft, loss or damage to persons, property or belongings of participants or accompanying persons, either before, during or following the congress, tours or their stay in Prague. It is therefore recommended that participants arrange their own personal health, accident and travel insurance.

PUBLIC TRANSPORT PASSES
Free public transport passes are provided for all delegates and are available for collection at the congress bag counter.

REGISTRATION
The registration area is located in the Forum Hall Foyer on the first floor of the congress centre. Please note that name badges must be worn at all times.

SPEAKERS’ ROOM
The Speakers’ Room is located in Meeting Room 2.1, on the second floor of the congress centre. Opening times are listed on the Facilities Timetable Overview. Facilities to review and amend presentations are available to all speakers and technical assistance will also be provided in this room. Please note that all speakers should submit their final PowerPoint presentation(s) to the Speakers’ Room no less than 3 hours in advance of their session. Speakers at early morning sessions are required to submit their material no later than 17:00 on the evening before their session is scheduled.

VENUE
Prague Congress Centre (Kongresové centrum Praha)
5. kvetna 65, 140 21 Prague 4, Czech Republic
Phone: +420 261 171 111 | Website: http://www.kcp.cz/en/homepage

WELCOME CEREMONY AND RECEPTION
All delegates are invited to attend the Welcome Ceremony which takes place from 18:30 to 19:30 on Sunday 11th September in the Congress Hall. The ceremony will open with welcomes from the ISOC Co-chairs and the ILAE President. This will be followed by the Awards Ceremony, in which the CEA awardees will be celebrated with short presentations. The ceremony will have a distinctly Czech flavour as Dr. Günter Kämper will give a talk on Epileptology and Prague, which will be followed by a performance by the local Black Light Theatre 5mec.

The ceremony will be immediately followed by a Welcome Reception, which all delegates are invited to join.

WHEELCHAIR ACCESS
The 12thECE venue is wheelchair accessible and assistance will be provided onsite to any wheelchair user.

WIFI
Free wifi is available in the venue for the duration of the congress to registered delegates.

Network name: Bial_Eisai@12ECE
Password: 12ece2016

The WIFI is supported by BIAL and Eisai.
PRAGUE TRANSPORT INFORMATION

Situated in the heart of Europe, Prague represents a major transport junction and an ideal strategic location for international meetings. The city has an efficient and safe public transport system which makes it very easy for visitors to get around.

BUSES

Buses (autobusy) cover the outskirts of Prague and areas where trams or the metro do not run. Bus 119 connects the Ruzyň airport with the Dejvická metro station and bus 100 connects the airport with the Zličín station. They are both a convenient and cheap way to get to and from the Prague airport.

TAXIS

There are a number of reputable Prague taxi companies that you can rely on for good service and fair rates:
- AAA Radiotaxi - www.aaa-taxi.cz
- City Taxi - www.citytaxi.cz
- Profi Taxi - www.profitaxi.cz
- Halotaxi - www.halotaxi.cz
- Sedop - www.sedop.cz

If you need to catch a taxi on the street, make sure it is a real, registered taxi. The yellow roof lamp must be permanently installed and must say TAXI in black letters on both sides. The driver’s name, licence number and rates should be printed on both front doors.

METRO (SUBWAY)

The Prague subway is fast, efficient, clean and easy to use. Its three lines consist of about 60 km of tracks, running mostly underground, and 57 stations. Trains arrive in 1-3 minute intervals during the peak hours of the morning and afternoon commute and in 4-10 minute intervals in the off-peak hours. All stations are equipped with escalators and about two thirds of all metro stations allow access for the disabled.

The Prague Congress Centre is adjacent to the Vyšehrad station on Metro Line C (Red Line), providing convenient access by public transport from the city centre and all major rail and bus stations.

Useful dictionary:
- eskalátor - escalator
- linka (A, B, C) - line (A, B, C)
- metro - subway
- přestup - transfer
- stanice metra - subway station
- trasa - route
- vstup - entrance
- výstup - exit
- Placený prostor, označte si jízdenku – Paid area, validate your ticket
TRAMS
With 500 km of tracks, trams (tramvaje) cover a large area of Prague and are used by some 300 million people a year. Daytime trams run from 04:30 until midnight in 8-10 minute intervals (8-15 minutes on weekends). Night trams (numbers 51-58) run from 00:30 until 04:30 in 40 minute intervals.
SCIENTIFIC PROGRAMME INFORMATION

SESSIONS
The sessions form the main part of the congress. The main topics were chosen by the International Scientific & Organising Committee (ISOC) and the sessions were selected from the numerous proposals submitted by ILAE members and other experts. These sessions were selected to represent the best in European and global epileptology.

Our programme covers all aspects of epileptology, but four main themes have been selected. Each day has different themes representing Basic Science, Paediatric Epilepsy, Pharmacotherapy and Epilepsy Surgery.

The titles of the four main sessions address the following topics:
- Trials and tribulations in the development of medical therapies
- Neurogenesis in epilepsy
- Challenges in the management of epilepsy in children - systems and technologies as solutions
- The changing landscape of epilepsy surgery; assessment and treatment

SPECIAL SYMPOSIA
Special symposia include the Chairs’ Symposium, which this year is dedicated to "Pharmacoresistant epilepsy from bench to seizure control". The symposium will address the issue of phenotyping of refractory adult and paediatric patients, preclinical models for pharmacoresistant epilepsies as well as new antiepileptic drugs (AEDs) and other future therapies beyond AEDs for the treatment of resistant epilepsies.

Two other special symposia entitled “Learning about focal ictogenesis from patients (and animal models)” and “The Michael Debate: Remission and epilepsy” will also form part of the scientific programme.

The programme will also feature the following joint symposia between the ILAE-Commission on European Affairs (CEA) and two other European societies:
- CEA – EAN (European Academy of Neurology) Symposium
- CEA – EMA (European Medicines Agency) Symposium

TEACHING SESSIONS
Teaching sessions will feature seven attractive, separate three-day, two-day and one-day morning series:

3 morning teaching sessions will be dedicated to VIREP Acourses.
The “How to do” series will also take place over three consecutive morning sessions. It will cover all aspects of clinical epileptology.
The “Seizure Cubs” series, with didactic video presentations of ictal semiology, will take place over two morning sessions.

There will be four other teaching sessions running over just one morning: “Autoimmune epilepsies; The risk/benefit stratification for epilepsy surgery”; “Pre-surgical evaluation”; “First seizures and early onset epilepsy”.

ECE TEACHING DAY
Thursday 15th September will feature three main courses.
A half-day course on “Seizures in emergency situations” will run from 08:00 to 12:30. This course will provide the audience with updated information on the two most relevant aspects of epileptology in the ICU: status epilepticus and the use, interpretation and impact of EEG in an intensive care unit environment.

An educational teaching course on “Pharmacological aspects of AEDs” will run for two hours.

A third teaching course primarily aimed at EEG technicians will run from 08:00 to 10:00. It will cover logistic and safety issues at the epilepsy monitoring unit. New systems for EEG reporting and practical tips for artefact recognition and management will be discussed. Experience with home video-EEG monitoring as a novel tool in epilepsy diagnostics will be presented.

ECE FORUMS
The ECE Forums were an innovation in the scientific programme of the 10th ECE in London, and following on from their success during the London (2012) and Stockholm (2014) ECEs, the innovative and popular ECE Forums will again form part of the programme for the Prague ECE.

They are designed to be sessions in which selected topics can be explored and discussed in an informal workshop or clubroom style. The topics have been selected from proposals made by ILAE members worldwide and generally focus on cutting-edge or controversial aspects of epilepsy work, not least including discussions on new or planned projects of general interest.

The sessions are intended to be creative and interactive, and are open free-of-charge to all participants of the congress.

AWARDS
We would like to congratulate the following awardees:

- Pavel Mareš – European Epileptology Award 2016
- Federico Vigevano – European Epileptology Award 2016
- Nana Tatishvili – European Epilepsy Education Award 2016
- Julia Jacobs – CEA Young Investigator Award 2016
- Nicola Specchio – CEA Young Investigator Award 2016
- Ioana Mindruta – Epileptic Disorders Prize 2016

All awards will be presented at the Welcome Ceremony on Sunday 11th September from 18:30-19:30.
The Symposium of Excellence in Epileptology, on Wednesday 14th September, will include lectures presented by the recipients of the 2016 European Epileptology Award, the CEA Young Investigator Award and the Epileptic Disorders Prize.

POSTER PRESENTATIONS AND PLATFORMS
112 of the best submitted abstracts have been selected by the International Scientific and Organising Committee for oral presentation and will be presented in Platform Sessions from Monday to Wednesday. There will be a special dedicated Platform Session for late breaking abstracts on Sunday 11th September.

Special attention has also been given to poster presentations during the congress. Posters will be on display from Monday to Wednesday and guided poster tours will be held at lunchtime, giving the opportunity to all authors to present their work and for delegates to ask questions.

HIGHLIGHTS SESSION
This concluding session is intended to give delegates an overview of the most important advancements that have been presented during the congress. Each main topic chair has been asked to summarise what they consider to be the highlights from presentations within their theme.
### SUNDAY 11TH SEPTEMBER 2016

#### Congress Hall | Forum Hall
---|---
09.00-09.30 | The Burden and Care of Epilepsy in Europe, Challenges of drug development for neonatal seizures
09.30-10.00 | Late breaking Abstracts, Break
10.00-10.30 | The Michael Debate: Remission and Epilepsy
10.30-11.00 | Welcome Ceremony, Welcome Reception
11.00-11.30 | Seizure detection in the EMU, MicroRNA as meta-controllers of gene expression in epilepsy
11.30-12.00 | Neuroinflammation: a treatment target for early life epileptic encephalopathies?
12.00-12.30 | SATELLITE SYMPOSIUM Contribution of epileptic sources to scalp EEG and MEG signals
12.30-13.00 | The Burden and Care of Epilepsy in Europe
13.00-13.30 | Challenges of drug development for neonatal seizures
13.30-14.00 | Late breaking Abstracts
14.00-14.30 | Break
14.30-15.00 | Welcome Ceremony, Welcome Reception
15.00-15.30 | Seizure detection in the EMU, MicroRNA as meta-controllers of gene expression in epilepsy
15.30-16.00 | Neuroinflammation: a treatment target for early life epileptic encephalopathies?
16.00-16.30 | SATELLITE SYMPOSIUM Contribution of epileptic sources to scalp EEG and MEG signals
16.30-17.00 | The Burden and Care of Epilepsy in Europe
17.00-17.30 | Challenges of drug development for neonatal seizures
17.30-18.00 | Late breaking Abstracts, Break
18.00-18.30 | Welcome Ceremony, Welcome Reception
18.30-19.00 | Seizure detection in the EMU, MicroRNA as meta-controllers of gene expression in epilepsy
19.00-19.30 | Neuroinflammation: a treatment target for early life epileptic encephalopathies?
19.30-20.00 | SATELLITE SYMPOSIUM Contribution of epileptic sources to scalp EEG and MEG signals
20.00-20.30 | The Burden and Care of Epilepsy in Europe
20.30-21.00 | Challenges of drug development for neonatal seizures
SCIENTIFIC PROGRAMME  
SUNDAY 11TH SEPTEMBER 2016

PARALLEL SESSION  
Congress Hall

14:30 – 16:00  The burden and care of epilepsy in Europe  
Co-chair: Jakob Christensen, Denmark  
Co-chair: Ettore Beghi, Italy

The prevalence of epilepsy: does it vary across Europe?  
Christine Linehan, Ireland

Assessing the cost of epilepsy: methodological aspects  
Poul Jønnum, Denmark

Epilepsy, stigma and quality of life: what is the situation in Europe?  
Ettore Beghi, Italy

ESBACE: an EU-funded study of the burden and care of epilepsy in Europe  
Jakob Christensen, Denmark

PARALLEL SESSION  
Forum Hall

14:30 – 16:00  Challenges of drug development for neonatal seizures  
Co-chair: Michele Simonato, Italy  
Co-chair: Cecilie Johannessen Landmark, Norway

Finding the right animal model  
Stéphane Auvin, France

Translational aspects – developing innovative drugs  
Aristea Galanopoulou, USA

Pitfalls of AED trials in neonatal seizures  
Ronit Pressler, United Kingdom

Developing innovative methods  
Catherine Chiron, France

PARALLEL SESSION  
South Hall

14:30 – 16:00  Seizure detection in the EMU (Epilepsy Monitoring Unit)  
Co-chair: Margitta Seeck, Switzerland  
Co-chair: Rainer Surges, Germany

Automatic seizure detection system for epilepsy monitoring units  
Christoph Baumgartner, Austria

The detection of active epilepsy in the scalp EEG  
Francesca Pittau, Switzerland

Seizure prediction and treatment using intracranial EEG  
Paul Boon, Belgium

Multi-model seizure detection, which modality tells us most?  
Sándor Beniczky, Denmark
**PARALLEL SESSION**
Meeting Hall I

14:30 – 16:00  
**MicroRNA as meta-controllers of gene expression in epilepsy: targets, diagnostics and opportunities for treatment**  
*Co-chair: Eleonora Aronica, Netherlands  
Co-chair: David Henshall, Ireland*  

**microRNA and inflammation: new therapeutic opportunities in epilepsy associated pathologies**  
Annamaria Vezzani, Italy  

**microRNA as mechanism-linked biomarkers of epileptogenesis**  
David Henshall, Ireland  

**Methodical approaches to PCR based quantification of miRNA in epilepsy**  
Petra Bencúrová, Czech Republic  

**microRNAs control neuronal morphology in health and disease**  
Vamshidhar Vangoor, Netherlands

**NEUROBIOLOGY SYMPOSIUM**
Panorama Hall

14:30 – 16:00  
**Learning about focal ictogenesis from patients (and animal models)**  
*Co-chair: Marco de Curtis, Italy  
Co-chair: Premysl Jirouska, Czech Republic*  

**Unit activity in human focal seizures**  
Wilson Truccolo, USA  

**Synchronization in human focal seizures**  
Kaspar Schindler, Switzerland  

**Onset, progression and termination of a focal seizure**  
Marco de Curtis, Italy  

**Interictal and ictal HFOs**  
Julia Jacobs, Germany

**PLATFORM SESSION**
Congress Hall

16:00 – 17:00  
**Late Breaking Abstracts**  
*Co-chair: Petr Marusic, Czech Republic  
Co-chair: Reetta Kälviäinen, Finland*
SCIENTIFIC PROGRAMME  
SUNDAY 11TH SEPTEMBER 2016

SPECIAL SYMPOSIUM
Forum Hall

16:30 – 18:00

The Michael Debate: Remission and epilepsy
Co-chair: Peter Wolf, Denmark
Co-chair: Vladimir Donáth, Slovakia

Basic mechanism of remission in epilepsy
Uwe Heinemann, Germany

Remission in benign childhood epilepsies
Helen Cross, United Kingdom

Remission in juvenile myoclonic epilepsy
Betül Baykan, Turkey

PARALLEL SESSION
South Hall

16:30 – 18:00

Neuroinflammation: a treatment target for early life epileptic encephalopathies?
Co-chair: Aristeia Galanopoulou, USA
Co-chair: Annamaria Vezzani, Italy

Perinatal inflammation: does it contribute to neurodevelopmental deficits?
Stefanie Dedeurwaerdere, Belgium

Early life inflammation: putative role in the pathogenesis of early life epileptic encephalopathies
Aristea Galanopoulou, USA

In vivo biomarkers of neuroinflammation: can they track disease progression?
Teresa Ravizza, Italy

From bench and bedside: can we envision novel pathway specific strategies for targeting neuroinflammation in early life epileptic encephalopathies?
Stéphane Auvin, France
SCIENTIFIC PROGRAMME

SUNDAY 11TH SEPTEMBER 2016

ECE FORUM
Panorama Hall

16:30 – 18:00

**Contribution of epileptic sources to scalp EEG and MEG signals**

*Chair: Louis Maillard, France*

**Observability and detectability of epileptic sources in EEG and MEG**
Christoph Michel, Switzerland

**Simultaneous intracerebral and scalp EEG correlates of temporal sources**
Laurent Koessler, France

**Simultaneous subdural- and scalp EEG correlates of frontal lobe epileptic sources**
Georgia Ramuntani, Germany

SATELLITE SYMPOSIUM
Meeting Hall I

16:30 – 18:00

Please see page 102 for full details on the satellite symposium
MONDAY 12TH SEPTEMBER 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Congress Hall</th>
<th>Forum Hall</th>
<th>South Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>VIREPA EEG basic and advanced courses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.00-08.30</td>
<td></td>
<td>How to do</td>
<td></td>
</tr>
<tr>
<td>08.30-09.00</td>
<td></td>
<td></td>
<td>Seizure Club I</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>Pharmaco-resistant epilepsy from bench to seizure control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30-10.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Antiepileptic Drugs 1</td>
<td>Clinical neurophysiology</td>
<td>Epilepsy in childhood</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-12.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-13.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00-13.30</td>
<td></td>
<td>Lunch and Posters</td>
<td></td>
</tr>
<tr>
<td>13.30-14.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>The current role of valproic acid in epilepsy therapy</td>
<td>PURKINJE’S SYMPOSIUM</td>
<td>The cerebellum and epilepsy</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00-18.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30-19.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00-19.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30-20.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.00-20.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.30-21.00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MONDAY 12TH SEPTEMBER 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting Hall I</th>
<th>Panorama Hall</th>
<th>Meeting Hall V</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>SATELLITE SYMPOSIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.00-08.30</td>
<td></td>
<td>Pre-surgical evaluation</td>
<td></td>
</tr>
<tr>
<td>08.30-09.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-09.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30-10.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-11.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-12.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-13.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00-13.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-14.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00-18.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30-19.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00-19.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30-20.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.00-20.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.30-21.00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Scientific Programme

Monday 12th September 2016

Teaching Session
Congress Hall

07:30 – 09:00
VIREPA EEG: basic and advanced courses

Co-chair Sándor Beniczky, Denmark
Co-chair Walter Van Emde Boas, Netherlands

VIREPA basic EEG course: the use and abuse of clinical EEG
Walter Van Emde Boas, Netherlands

VIREPA advanced EEG course: source localization in the clinical practice
Sándor Beniczky, Denmark

Teaching Session
Forum Hall

07:30 – 09:00
How to do

Co-chair Christian Elger, Germany
Co-chair Dieter Schmidt, Germany

How to diagnose an event as either epileptic or non epileptic
Christian Elger, Germany

How to decide when and how to start drug therapy
Dieter Schmidt, Germany

Teaching Session
South Hall

07:30 – 09:00
Seizure Club I

Co-chair Philippe Kahane, France
Co-chair Hans Holthausen, Germany

Case presentations and discussion
Milan Brázdil, Czech Republic
Margitta Seeck, Switzerland
Philippe Kahane, France
Hans Holthausen, Germany

Satellite Symposium
Meeting Hall I

07:30 – 09:00
Please see page 102 for full details on the satellite symposium

Teaching Session
Panorama Hall

07:30 – 09:00
Pre-surgical evaluation

Co-chair Ivan Rektor, Czech Republic
Co-chair Felix Rosenow, Germany

Concept of presurgical evaluation, indications, neuropsychology
Kristina Malmgren, Sweden

Non-invasive investigation (video-EEG monitoring, imaging methods)
Petr Marusic, Czech Republic

Invasive video-EEG monitoring, ictal manifestations
Ivan Rektor, Czech Republic
09:00 – 11:00  **Pharmaco-resistant epilepsy from bench to seizure control**  
*Co-chair: Milan Brázdiil, Czech Republic  
Co-chair: Meir Bialer, Israel*  
— Phenotyping of refractory adult patients with epilepsy: where does it help?  
Simon Shorvon, United Kingdom  
— Phenotyping of refractory paediatric patients with epilepsy: where does it help?  
Sameer Zuberi, United Kingdom  
— Preclinical models for pharmaco-resistant epilepsies  
Hana Kubová, Czech Republic  
— New antiepileptic drugs with potential for therapy-resistant epilepsy  
Michael Rogawski, USA  
— Are there future therapies in pharmaco-resistant epilepsies beyond antiepileptic drugs?  
Kristl Vonck, Belgium

11:30 – 13:00  **Antiepileptic drugs 1**  
*Co-chair: Svein Johannessen, Norway  
Co-chair: Nicola Specchio, Italy*  
— Prescribing trends for sodium valproate in Ireland  
Sinead Murphy, Ireland  
— Marked reduction in secondarily generalized seizures in patients treated with perampanel for 3 and 4 years  
Emilio Perucca, Italy  
— Efficacy and tolerability of lacosamide monotherapy in patients with newly diagnosed epilepsy: a prospective randomized double-blind non-inferiority trial versus controlled-release carbamazepine  
Michel Baulac, France  
— Possible clinically relevant interactions between antiepileptic drugs and other prescription medications in elderly patients with newly diagnosed epilepsy  
Tapani Käränen, Finland  
— Discontinuation of the first antiepileptic drug in patients with epilepsy in the general population: rate and predictors  
Ettore Beghi, Italy  
— Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit  
Alexandra Rohracher, Austria
**Scientific Programme**

**MONDAY 12th SEPTEMBER 2016**

**Platform Session**

**Forum Hall**

11:30 – 13:00

**Clinical Neurophysiology**

*Co-chair: Uwe Heinemann, Germany*
*Co-chair: Francesca Pittau, Switzerland*

- Source localization of interictal activity in suspected extra-temporal drug-resistant focal epilepsy: a prospective high-density EEG and stereo-EEG study
  *Steve Gibbs, Canada*

- What different intracranial EEG seizure patterns can tell us about ictogenic mechanisms
  *Vadym Gnatkovsky, Italy*

- Frequency-dependent changes of neural networks from pre-ictal to ictal stages in childhood absence epilepsy
  *Xiaoshan Wang, China*

- Seizure onset patterns in focal cortical dysplasia and neurodevelopmental tumours: relationship with surgical prognosis and neuropathological subtypes
  *Stanislas Lagarde, France*

- A novel model-based method for real-time detection of electrographic seizures
  *Armen Sargsyan, Australia*

- Epilog: a framework for automatic detection of epileptic spikes and subsequent EEG source imaging to localize the epileptogenic zone with high sensitivity and specificity
  *Pieter van Mierlo, Belgium*

---

**Platform Session**

**South Hall**

11:30 – 13:00

**Epilepsy in Childhood**

*Co-chair: Vladimir Komárek, Czech Republic*
*Co-chair: Floor Jansen, Netherlands*

- Clinico-neurophysiological and genetic features of ESES/CSWS in Denmark
  *Daniella Terney, Denmark*

- Cognitive problems among children exposed to antiepileptic drugs. Preliminary data
  *Lars Skou Elkjær, Denmark*

- Emotional functioning, fatigue, sleep quality and stress in parents of children with early onset epilepsy: a population-based study
  *Chloe Jones, United Kingdom*

- Parent reported child development, quality of life and family stress data from a Scottish population based cohort of children with newly diagnosed epilepsy
  *Jack Waldman, United Kingdom*

- Perception of epilepsy by epileptic children, their parents and doctors
  *Nebal Waill Saad, Iraq*

- Three-month outcomes of an RCT psychosocial group intervention for young people with epilepsy (PIE)
  *Liam Dorris, United Kingdom*
12th European Congress on Epileptology

SCIENTIFIC PROGRAMME

MONDAY 12TH SEPTEMBER 2016

PLATFORM SESSION
Meeting Hall I

11:30 – 13:00  Basic science 1

Co-chair Julia Jacobs, Germany
Co-chair Pavel Mares, Czech Republic

Correlation of epileptiform activity and c-fos mRNA expression in an acute in vitro model of epilepsy
Sophie Schlabitz, Germany

Dual and opposing roles of miR-124 in epileptogenesis are mediated through NRSF and inflammatory pathways
Gary Brennan, Ireland

Accessory β subunits are protective towards gating modifications induced by Dravet syndrome NaV1.1 sodium channel truncated mutants
Massimo Mantegazza, France

Hippocampal cellular prion protein expression in the pilocarpine model of temporal lobe epilepsy
Kelin Cristine Martin, Brazil

QTc prolongation in an experimental epilepsy model
Sofia Markoula, United Kingdom

Distribution of neuronal tissue damage in epilepsy surgery specimens
Laura Rossini, Italy

SPECIAL SYMPOSIUM
Panorama Hall

11:30 – 13:00  From clinical trials to clinical practice: what kind of evidence do we need?

Co-chair Jacqueline French, USA
Co-chair Manuel Haas, United Kingdom

Development of anti-epileptic drugs for young children
Alexis Arzimanoglou, France

Shortening placebo exposure in anti-epileptic drug trials
Emilia Bagiella, USA

Treatments for acute seizures and status epilepticus
Eugen Trinka, Austria
**Scientific Programme**
**Monday 12th September 2016**

**Parallel Session**
Forum Hall

14:30 – 16:00

**The current role of valproic acid in epilepsy therapy**
Co-chair: Svein Johannessen, Norway
Co-chair: Matthew Walker, United Kingdom

The story of valproate and how it changed the course of history of epilepsy treatment
Simon Shorvon, United Kingdom

How valproic acid structure and clinical experience affected the design of its 2nd generation antiepileptic drugs?
Meir Bialer, Israel

Is valproic acid such a terrible teratogen? From the basic science point of view
Richard Finnell, USA

Clinical teratogenicity and impact of EMA’s warning on the use of valproic acid in women
Torbjörn Tomson, Sweden

**Parallel Session**
South Hall

14:30 – 16:00

**Purkinje’s Symposium – The cerebellum and epilepsy**
Co-chair: Philippe Kahane, France
Co-chair: Kristina Malmgren, Sweden

Cerebellar connections and interactions with the cerebral cortex
Richard Apps, United Kingdom

Epilepsy and cerebellar atrophy
Milan Brázda, Czech Republic

Cerebellar epilepsy – is it a myth?
Hans Holthausen, Germany

Cerebellar neurostimulation in the treatment of epilepsy
Gregory Krauss, USA
PARALLEL SESSION
Meeting Hall I

14:30 – 16:00
Epilepsy and intellectual disability

Co-chair: Christian Brandt, Germany
Co-chair: Christoph Helmstaedter, Germany

Epidemiology of epilepsy and intellectual disability in Europe
Christine Linehan, Ireland

Efficacy of antiepileptic drug treatment in persons with epilepsy and intellectual disability
Michael Kerr, United Kingdom

Assessment of drug side effects in persons with intellectual disability
Christian Brandt, Germany

Epilepsy surgery in patients with epilepsy and intellectual disability
Vicente Villanueva, Spain

---

PARALLEL SESSION
Panorama Hall

14:30 – 16:00
Mechanisms of epileptogenicity in human brain lesions

Co-chair: Albert Becker, Germany
Co-chair: Dimitri Kullmann, United Kingdom

Mechanisms underlying seizure generation around human glioma
Gilles Huberfeld, France

LIM-domain-binding proteins: role for epilepsy development in glioneuronal tumors
Albert Becker, Germany

Selective silencing of parvalbumin interneurons in the subiculum induces recurrent spontaneous seizures
Günther Sperk, Austria

Impaired intrinsic plasticity in hippocampal epileptogenesis
Yoel Yaari, Israel
12th European Congress on Epileptology

SCIENTIFIC PROGRAMME

MONDAY 12TH SEPTEMBER 2016

PLATFORM SESSION

Meeting Hall V

14:30 – 16:00

Epidemiology

Co-chair: Ettore Beghi, Italy
Co-chair: Gunter Krämer, Switzerland

A multi-cohort approach to establishing major depressive disorder as both an independent risk factor and modifier of the expression of epilepsy
Colin Josephson, Canada

Selective serotonin reuptake inhibitors and risk of posttraumatic epilepsy – a population based cohort study
Jakob Christensen, Denmark

The risk of seizure recurrence and clinical predictors in patients with defined epileptic syndromes: a prospective study
Elisa Bruno, Italy

Prevalence of autoimmune temporal lobe epilepsy
Martin Elsak, Czech Republic

The incidence of SUDEP: a nationwide population-based study
Olafur Sveinsson, Sweden

Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)
Melissa Maguire, United Kingdom

SATELLITE SYMPOSIUM

Forum Hall

16:30 – 18:00

Please see page 102 for full details on the satellite symposium
### TUESDAY 13TH SEPTEMBER 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Forum Hall</th>
<th>South Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>VIREPA Neuroimaging and medical treatment of epilepsy</td>
<td>How to do</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30-09.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-09.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Trials and Tribulations in the Development of Medical Therapies</td>
<td>The changing landscape of epilepsy surgery: assessment and treatment</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-11.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-12.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-13.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00-13.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-14.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td>Novel therapies for status epilepticus (SE)</td>
<td>MARCUS MARCI’S SYMPOSIUM</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td>What is a seizure? New perspectives</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00-18.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30-19.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00-19.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30-20.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.00-20.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.30-21.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Meeting Hall I

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.30-19.00</td>
<td>11th European Congress on Epileptology</td>
</tr>
</tbody>
</table>

### Panorama Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.00-19.30</td>
<td>11th European Congress on Epileptology</td>
</tr>
</tbody>
</table>

### Meeting Hall V

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.30-20.00</td>
<td>11th European Congress on Epileptology</td>
</tr>
</tbody>
</table>

**Satellite Symposium**

- Seizure Club II
- SATELLITE SYMPOSIUM
- The risk/benefit stratification for Epilepsy Surgery
SCIENTIFIC PROGRAMME  TUESDAY 13TH SEPTEMBER 2016

TEACHING SESSION  Forum Hall

07:30 – 09:00  VIREPA courses on neuroimaging and medical treatment of epilepsy

Co-chair: Janet Mifsud, Malta
Co-chair: Petr Marusic, Czech Republic

VIREPA neuroimaging course
Petr Marusic, Czech Republic

VIREPA course on medical treatment of epilepsy
Janet Mifsud, Malta

TEACHING SESSION  South Hall

07:30 – 09:00  How to do

Co-chair: Christian Elger, Germany
Co-chair: Dieter Schmidt, Germany

How to select the special AED
Dieter Schmidt, Germany

How to deal with pharmacoresistance
Christian Elger, Germany

SCIENTIFIC PROGRAMME  TUESDAY 13TH SEPTEMBER 2016

TEACHING SESSION  Meeting Hall I

07:30 – 09:00  Seizure Club II

Chair: Christoph Baumgartner, Austria

Case presentations and discussion
Christoph Baumgartner, Austria
Walter Van Emde Boas, Netherlands
Ivan Rektor, Czech Republic
Felix Rosenow, Germany

SATELLITE SYMPOSIUM  Panorama Hall

07:30 – 09:00  Please see page 102 for full details on the satellite symposium

TEACHING SESSION  Meeting Hall V

07:30 – 09:00  The risk/benefit stratification for epilepsy surgery

Co-chair: Pavel Krsék, Czech Republic
Co-chair: Andreas Schulze-Bonhage, Germany

Efficacy and prognostic factors of surgical procedures
Serge Vuillemez, Switzerland

Medical and psychosocial risks of surgical procedures
Kristina Malmgren, Sweden

Risk stratification: risk/benefit ratio and hierarchy of procedures
Michael Sperling, USA
SCIENTIFIC PROGRAMME

TUESDAY 13TH SEPTEMBER 2016

MAIN SESSION
Forum Hall

09:00 – 11:00

Trials and tribulations in the development of medical therapies
Co-chair Christian Elger, Germany
Co-chair Jacqueline French, USA

Seizure counting and its consequences for clinical trials in epilepsies
Christian Elger, Germany

Relationships between efficacy and placebo rates
Sylvian Rheims, France

Open vs. blinded trials in epilepsy
Tony Marson, United Kingdom

Monotherapy trials in epilepsy: are they necessary and how should they be designed?
Jacqueline French, USA

SCIENTIFIC PROGRAMME

TUESDAY 13TH SEPTEMBER 2016

MAIN SESSION
South Hall

09:00 – 11:00

The changing landscape of epilepsy surgery: assessment and treatment
Co-chair Magritta Seeck, Switzerland
Co-chair Petr Marusic, Czech Republic

The true outcome of surgical therapy in the 21st Century in Europe
Margritta Seeck, Switzerland

Why don’t patients get epilepsy surgery?
Eva Kumlien, Sweden

Antiepileptic drug withdrawal after epilepsy surgery
Kees Braun, Netherlands

The future of epilepsy surgery techniques
Karl Schaller, Switzerland
11:30 – 13:00

**Antiepileptic drugs 2**

**Co-chair: Norman Delanty, Ireland**
**Co-chair: Cecilie Johannessen Landmark, Norway**

Pharmacokinetic and pharmacodynamic analysis after various routes of administration of sec-butylpropylacetamide (SPD), a new CNS drug possessing a unique activity against status epilepticus
David Bibi, Israel

Pharmacokinetic variability of valproate in women of childbearing age and during pregnancy
Cecilie Johannessen Landmark, Norway

The role of anti-epileptic drugs as a cause of behavioral problems in children with tuberous sclerosis complex: a retrospective cohort study
Hanna Hulshof, Netherlands

EARLY-ESLI study: efficacy, tolerability and conversion to monotherapy with eslicarbazine acetate after first monotherapy failure
Vicente Villanueva, Spain

Retrospective study about effectiveness and tolerability of perampanel in drug resistant myoclonic epilepsies
Francisco Gil, Spain

Safety aspects of antiepileptic drugs used in epilepsy and other indications in Norway
Arton Baftiu, Norway

---

**Neuroimaging**

**Co-chair: Kees Braun, Netherlands**
**Co-chair: Hajo Hamer, Germany**

Two for the price of one. The combination of EEG-fMRI and ESI contributes to the localization of epileptogenic region and is highly predictive of seizure outcome
Maria Centeno, United Kingdom

Resting state functional connectivity alterations by independent component analysis correspond with intra-operative EEG in prospective large pediatric intractable epilepsy study
Varina Boerwinkle-Wolf, USA

7 tesla MRI in the pre-surgical evaluation of patients with refractory focal epilepsy
Tim Veersema, Netherlands

Simultaneous EEG and functional MRI at ultra-high field (7T) in epilepsy: Feasibility and first results
Francesca Pittau, Switzerland

Connectivity in ictal SPECT perfusion: a cortico-cortical evoked potential study
Simon Tousseyn, Belgium

Magnetoecephalography-guided frontal lobe epilepsy surgery using neuronavigation and intraoperative MR imaging
Björn Sommer, Germany
PAEDIATRICS
BASIC SCIENCE
PHARMACOLOGY
SURGERY
OTHER CATEGORY
DIAGNOSTICS
EPIDEMIOLOGY
SEMIology AND CLASSIFICATION

SCIENTIFIC PROGRAMME  TUESDAY 13TH SEPTEMBER 2016

PLATFORM SESSION
Meeting Hall I

11:30 – 13:00

Epileptic encephalopathies

Co-chair: Vladimir Komdrek, Czech Republic
Co-chair: Patrick Van Bogaert, Belgium

Targeted resequencing in epileptic encephalopathies: diagnostic implications and genotype–phenotype correlations
Pasquale Striano, Italy

The molecular and phenotypic spectrum of IQSEC2 related epilepsy
Ayelet Zerem, Israel

Late breaking abstract
TBC

Epileptic phenotype in children with early onset mitochondrial diseases
Sara Matricardi, Italy

Epileptic encephalopathy with electrical status epilepticus in sleep: correlation of EEG network characteristics and IQ
Bart Van den Munckhof, Netherlands

Electro-clinical features of a new channelopathy due to loss of function or gain of function mutations in KCNA2
Guido Rubboli, Denmark

PAEDIATRICS
BASIC SCIENCE
PHARMACOLOGY
SURGERY
OTHER CATEGORY
DIAGNOSTICS
EPIDEMIOLOGY
SEMIology AND CLASSIFICATION

SCIENTIFIC PROGRAMME  TUESDAY 13TH SEPTEMBER 2016

PLATFORM SESSION
Panorama Hall

11:30 – 13:00

Status epilepticus

Co-chair: Mar Carreño, Spain
Co-chair: Simon Shorvon, United Kingdom

Etiology and clinical characteristics of convulsive status epilepticus as initial epileptic event: a cohort of 236 children
Ruzica Kravljanc, Serbia

Falling status epilepticus mortality rates in England & Wales: 2001-2013?
Aidan Neligan, United Kingdom

Treatment delays of prolonged and recurrent epileptic seizures
Joni Saarinen, Finland

GPED voltage maps as distinctive biomarkers between non convulsive status epilepticus and anoxic brain injury
Dimitris Sakellariou, Greece

Refractory status epilepticus: potential prognostic markers and clinical outcomes
Montserrat Gonzalez-Cuevas, Spain

Population-based evaluation of treatment costs of super-refractory status epilepticus (SRSE) in Germany
Adam Strzelczyk, Germany
**Scientific Programme**

**TUESDAY 13th SEPTEMBER 2016**

**PLATFORM SESSION**

Meeting Hall V

11:30 – 13:00

**Basic science 2**

Co-chair: Stefanie Dereurwaerdere, Belgium
Co-chair: Michael Rogawski, USA

L-alpha-glycerylphosphorylcholine (α-GPC) enhances hippocampal neurogenesis and cognitive function in pilocarpine seizure-induced neuronal death and cognitive impairment

Joo Young Lee, Korea, Republic of

Attenuation of the changes in the expression of BDNF and c-fos in adult mice brain undergoing kindling: implications for antiepileptogenic properties of novel antiepileptic compound isoxylitones [E/Z]

Shabana U. Simjee, Pakistan

Effect of newly designed mTOR inhibitors on target activation and seizure threshold in healthy versus epileptic mice

Claudia Brandt, Lower Saxony, Germany

Systemic delivery of antagonim-134 produces anti-epileptogenic effects

Cristina Ruedell Reschke, Dublin, Ireland

Protective effects of fingolimod on epileptogenesis and neuropsychiatric comorbidities in WAG/Rij rats, a genetic animal model of absence epilepsy and depressive-like behaviour

Emilio Russo, Italy

Three-stage anticonvulsant screening program for chronic epilepsy

Kevin J. Staley, MA, USA

**PARALLEL SESSION**

Forum Hall

14:30 – 16:00

**Novel therapies for status epilepticus (SE)**

Co-chair: Reetta Kälviäinen, Finland
Co-chair: Eugen Trinka, Austria

New approaches to treatment of acute seizures and the early stage of status epilepticus

Simon Shorvon, United Kingdom

The potential of valproic acid derivatives valnoctamide and SPD in treatment of benzodiazepine-resistant status epilepticus (stage of established status epilepticus)

Meir Bialer, Israel

Allopregnanolone (SAGE 547) potential in the treatment of refractory and super refractory status epilepticus

Michael Rogawski, USA

Challenges for novel therapies in the acute epilepsy setting – industry perspective

Konrad Werhahn, Germany
PARALLEL SESSION
South Hall

14:30 – 16:00

Marcus Marci’s Symposium – What is a seizure? New perspectives
Co-chair: John Jefferys, United Kingdom
Co-chair: Viktor Jirsa, France

Are seizures really random events?
Premysl Jiruska, Czech Republic

Common principles of seizures: from cells to human brain
Viktor Jirsa, France

Neuronal behavior during seizure: insights from human patients
Catherine Schevon, USA

Genetic therapy to control seizures in humans – sci-fi or reality?
Robert Wykes, United Kingdom

PARALLEL SESSION
Meeting Hall I

14:30 – 16:00

Alterations of consciousness in epilepsy: A developmental trajectory?
Co-chair: Andrea Cavanna, United Kingdom
Co-chair: Adam Zeman, United Kingdom

Common mechanism of loss of consciousness in seizures
Hal Blumenfeld, USA

Ictal consciousness in children with temporal lobe epilepsy: clinical, neurophysiological and neuroimaging correlates
Stefano Seri, United Kingdom

Intracranial recording and ictal consciousness in temporal lobe epilepsy
Fabrice Bartolomei, France

Clinical assessment of ictal consciousness in epilepsy across the lifespan
Andrea Cavanna, United Kingdom
14:30 – 16:00  ATP1A3 related epilepsies: novel phenomena, therapeutic insights and underlying pathophysiology

Co-chair: Alexis Arzimanoglou, France
Co-chair: Catherine Chiron, France

Epilepsies in alternating hemiplegia of childhood and other ATP1A3 related diseases by Eleni Panagiotakaki (France) and Hendrik Rosewich (Germany)
Eleni Panagiotakaki, France

Acute and long term management of seizures and related disorders in alternating hemiplegia of childhood
Federico Vigevano, Italy

Underlying pathophysiology of ATP1A3 related epilepsies: animal models and the promise of novel therapies
Mohamad Mikati, USA

14:30 – 16:00  The mysteries of insular epilepsy

Co-chair: Milan Bradzdiil, Czech Republic
Co-chair: Mark Richardson, United Kingdom

Anatomo-functional organisation of the insular cortex: the many faces of a small island
François Mauguière, France

Electroclinical manifestations of insular seizures: the great mimicker
Philippe Kahane, France

Insular seizures and SUDEP
Rainer Surges, Germany

Surgery of insular epilepsy: yes, you can!
Pavel Kršek, Czech Republic

16:30 – 18:00  Please see page 102 for full details on the satellite symposium
**SCIENTIFIC PROGRAMME**

**TUESDAY 13TH SEPTEMBER 2016**

**ECE FORUM**

**Forum Hall**

18:00 – 19:30

**Novel predictive biomarkers of epileptogenesis and therapy response: bedside to bench-and back**

*Co-chair: Stéphane Auvin, France*
*Co-chair: Lieven Lagae, Belgium*

**PET imaging as a biomarker of epileptogenesis**

Stefanie Dedeurwaerdere, Belgium

**A novel serum neuroinflammatory biomarker of epileptogenesis that predicts response to therapy: preclinical and clinical evidence**

Lauren Walker, United Kingdom

**Astrocytic myo--inositol on MRS together with cognitive deficits predict epilepsy development in experimental epilepsy models**

Teresa Ravizza, Italy

**EEG tracking of epileptogenesis and therapeutic response in TSC patients**

Lieven Lagae, Belgium

---

**ECE FORUM**

**South Hall**

18:00 – 19:30

**Treatment adherence in epilepsy: an undervalued subject**

*Co-chair: Antonio Martins da Silva, Portugal*
*Co-chair: Emilio Perucca, Italy*

**Minimization of AED effects that could influence adherence to treatment**

Emilio Perucca, Italy

**Adherence to medication in epilepsy and consequences of non-adherence**

Torbjörn Tomson, Sweden

**Adherence to treatment among patients with epilepsy: the patients’ perspectives**

Robert Horne, United Kingdom

---

**ECE FORUM**

**Meeting Hall I**

18:00 – 19:30

**Horizons for Dravet Syndrome: update**

*Co-chair: Tiziana Granata, Italy*
*Co-chair: Bernardo Dalla Bernardina, Italy*

**Roundtable Discussion**

Renzo Guerrini, Italy
Rima Nabbout, France
Massimo Mantegazza, France
Helen Cross, United Kingdom
Ana Mingorance-Le Meur, Spain
Catherine Chiron, France
Scientific Programme
Tuesday 13th September 2016

Platform Session
Panorama Hall

18:00 – 19:30

Genetics

Co-chair: Ingo Helbig, Germany
Co-chair: Katja Kobow, Germany

Whole exome sequencing in the epilepsies: the developing diagnostic exome signature of epilepsy genes over a five-year period
Katherine Helbig, USA

Genetics of sleep-related hypermotor epilepsy (SHE): whole exome sequencing (WES) analysis in a large Italian cohort
Laura Licchetta, Italy

A prospective whole Scottish population study of genetic and immune causes of epilepsy and complex febrile seizures in children under 3 years of age: The Genetic and Autoimmune Childhood Epilepsy (GACE) Study
Joseph Symonds, United Kingdom

Search for de novo variants in microRNA genes that cause epileptic encephalopathies
Jolien Roovers, Belgium

Detection of rare mutations with therapeutic relevance in infants with genetic epilepsy: the great benefit of NGS diagnostics
Oliver Puk, Germany

Epileptic phenotype in patients with AP4M1 mutations
Marie Therese Abi Warde, France

Platform Session
Meeting Hall V

18:00 – 19:30

Epilepsy and cognition

Co-chair: Paul Boon, Belgium
Co-chair: Liam Dorris, United Kingdom

Daytime naps, night time sleep and everyday memory in adults with epilepsy
Zoe C. Thayer, Australia

Nocturnal supervision at an epilepsy residential setting
Marije van der Lende, Netherlands

The long-term cognitive outcomes after anterior temporal lobectomy
Anna Rita Giovagnoli, Italy

A cognitive-behavioral intervention (HOBSCOTCH) improves quality of life and attention in epilepsy: A pilot study
Barbara Jobst, USA

COgnitive behavioural therapy vs standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES): progress in a randomised controlled trial
Laura Goldstein, United Kingdom

An RCT of self-management education in epilepsy: characteristics of participants at baseline
Leone Ridsdale, United Kingdom
### WEDNESDAY 14TH SEPTEMBER 2016

#### Forum Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>Paediatric and sleep courses</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td>How to</td>
</tr>
<tr>
<td>08.30-09.00</td>
<td>Challenges in the management of epilepsy in children – systems and technology as solutions</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>Neurogenesis in epilepsy</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Break</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Antiepileptic Drugs 3</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Surgical treatment</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>The life cycle of antiepileptic drugs</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Seizures and stroke: from bad to worse and what could be done about it?</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>Lunch and Posters</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Epilepsy Syndromes</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>MENDEL’S SYMPOSIUM</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>GENETIC (IDIOPATHIC) FOCAL EPILEPSIES – “BENIGN” NO MORE?</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td>Break</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>Genetic (idiopathic) focal epilepsies with sleep activation – “benign” no more?</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>The neurobiology of Focal Cortical Dysplasias (FCD) – new genes, mechanisms and diagnostic tools</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td>Epilepsy management in countries with limited resources</td>
</tr>
<tr>
<td>17.30-18.00</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
<tr>
<td>18.00-18.30</td>
<td>Epilepsy management in countries with limited resources</td>
</tr>
<tr>
<td>18.30-19.00</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
<tr>
<td>19.00-19.30</td>
<td>Epilepsy management in countries with limited resources</td>
</tr>
<tr>
<td>19.30-20.00</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
<tr>
<td>20.00-20.30</td>
<td>Epilepsy management in countries with limited resources</td>
</tr>
<tr>
<td>20.30-21.00</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
</tbody>
</table>

#### South Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>Paediatric and sleep courses</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td>How to</td>
</tr>
<tr>
<td>08.30-09.00</td>
<td>Challenges in the management of epilepsy in children – systems and technology as solutions</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>Neurogenesis in epilepsy</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Break</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Antiepileptic Drugs 3</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Surgical treatment</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>The life cycle of antiepileptic drugs</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Seizures and stroke: from bad to worse and what could be done about it?</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>Lunch and Posters</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Epilepsy Syndromes</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>MENDEL’S SYMPOSIUM</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>GENETIC (IDIOPATHIC) FOCAL EPILEPSIES – “BENIGN” NO MORE?</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td>Break</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>Genetic (idiopathic) focal epilepsies with sleep activation – “benign” no more?</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>The neurobiology of Focal Cortical Dysplasias (FCD) – new genes, mechanisms and diagnostic tools</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td>Epilepsy management in countries with limited resources</td>
</tr>
<tr>
<td>17.30-18.00</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
<tr>
<td>18.00-18.30</td>
<td>Epilepsy management in countries with limited resources</td>
</tr>
<tr>
<td>18.30-19.00</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
<tr>
<td>19.00-19.30</td>
<td>Epilepsy management in countries with limited resources</td>
</tr>
<tr>
<td>19.30-20.00</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
<tr>
<td>20.00-20.30</td>
<td>Epilepsy management in countries with limited resources</td>
</tr>
<tr>
<td>20.30-21.00</td>
<td>When epilepsy sets in – your (family/personal) life</td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAMME | WEDNESDAY 14TH SEPTEMBER 2016

TEACHING SESSION
Forum Hall

07:30 – 09:00
VIREPA EEG: paediatric and sleep courses

Co-chair: Monika Eisermann, France
Co-chair: Al de Weerd, Netherlands

VIREPA paediatric EEG course: from polygraphic video-EEG recording to seizure type and syndrome diagnosis
Monika Eisermann, France

Virepa EEG course on sleep: epilepsy and sleep
Al de Weerd, Netherlands

TEACHING SESSION
South Hall

07:30 – 09:00
How to do

Co-chair: Christian Elger, Germany
Co-chair: Dieter Schmidt, Germany

How to decide for epilepsy surgery
Christian Elger, Germany

How and when to end therapy
Dieter Schmidt, Germany

SCIENTIFIC PROGRAMME | WEDNESDAY 14TH SEPTEMBER 2016

TEACHING SESSION
Meeting Hall I

07:30 – 09:00
First seizures and early onset epilepsy: the need to review our current practices

Co-chair Dana Craiu, Romania
Co-chair Stefano Seri, United Kingdom

Expert epileptology work-up after a first unprovoked seizure
Margitta Seeck, Switzerland

MRI after the first seizure
Roland Wiest, Switzerland

When is it safe to return driving after a first seizure?
Tony Marson, United Kingdom

Comorbidities are crucial for the prognosis of early onset epilepsy
Christoph Baumgartner, Austria

SATELLITE SYMPOSIUM
Panorama Hall

07:30 – 09:00
Please see page 102 for full details on the satellite symposium
**PAEDIATRICS**  **BASIC SCIENCE**  **PHARMACOLOGY**  **SURGERY**  **OTHER CATEGORY**  **DIAGNOSTICS**  **EPIDEMIOLOGY**  **SEMIOTIC AND CLASSIFICATION**  **Scientific Programme**  **Scientific Programme**

---

**TEACHING SESSION**
Meeting Hall V

07:30 – 09:00

**Autoimmune epilepsies**

*Co-chair: Petr Marusic, Czech Republic*
*Co-chair: Christian Bien, Germany*

**Clinical phenotypes**
David Krysl, Czech Republic

**Indications for testing autoantibodies in patients with epilepsy**
Christian Bien, Germany

**Immunotherapies – when to start, which drugs and when to stop**
Sarosh Irani, United Kingdom

---

---

---

**MAIN SESSION**
Forum Hall

09:00 – 11:00

**Challenges in the management of epilepsy in children – systems and technology as solutions**

*Co-chair: Sameer Zuberi, United Kingdom*
*Co-chair: Peter Uldall, Denmark*

**Clinical networks – breaking barriers between primary, secondary & tertiary care**
Sameer Zuberi, United Kingdom

**The internet, apps & social media – education, interaction & management**
Kate Riney, Australia

**Guidelines, pathways & checklists – raising standards or preventing personalized care?**
Dana Crala, Romania

**Alarms & monitors – distractions or life savers?**
Lieven Lagae, Belgium
SCIENTIFIC PROGRAMME

WEDNESDAY 14TH SEPTEMBER 2016

MAIN SESSION
South Hall

09:00 – 11:00

Neurogenesis in epilepsy
Co-chair: Hana Kubová, Czech Republic
Co-chair: Helen Scharffman, USA

Adult neurogenesis: from genes to brain function
Sebastian Jessberger, Switzerland

Neurogenesis in epileptic brain: possible target for therapy?
Helen Scharffman, USA

Neurogenesis in epileptic brain: does it contribute to epileptic comorbidities?
Gerd Kempermann, Germany

Does neurogenesis happen in the human brain?
Embla Steiner, Sweden

11:30 – 13:00

Antiepileptic drugs 3
Co-chair: Michael Rogawski, USA
Co-chair: Vicente Villanueva, Spain

A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy
Francesco Brigo, Italy

Myoclonic and absence seizures in patients with idiopathic generalized epilepsy (IGE): exploratory outcomes in a phase III PTGC study with adjunctive perampanel
Terence O’Brien, Australia

Efficacy of eslicarbazepine acetate versus controlled-release carbamazepine as monotherapy in patients with newly diagnosed partial-onset seizures
Eugen Trinka, Austria

A review of the drug–drug interactions of the new antiepileptic drug brivaracetam
Brian D. Moseley, USA

Intracerebroventricular cerépionase alfa (BMN 190) in children with CLN2 disease: results from a phase 1/2, open-label, dose-escalation study
Nicola Specchio, Italy

Cognition improves via immunotherapy in patients with onconeural but not GAD65 autoantibody-associated limbic encephalitis
Niels Hansen, Germany
11:30 – 13:00  Surgical treatment

Co-chair: Kristina Malmgren, Sweden
Co-chair: Sylvain Rheims, France

Can histologically normal epileptogenic zone share common electrophysiological phenotypes with focal cortical dysplasia? SEEG-based study in MRI-negative epileptic patients
Julia Scholly, France

Increased subcortical oligodendroglia-like cells in pharmaco-resistant focal epilepsy in children correlate with extensive epileptogenic zone
Satoru Sakuma, Canada

Stereotactic radiofrequency thermocoagulation for hypothalamic hamartoma
Hiroshi Shirozu, Japan

Electrical stimulation of the anterior nucleus of the thalamus for the treatment of intractable epilepsy: a longitudinal data analysis
Won Gu Lee, Korea, Republic of

Increased seizure frequency after epilepsy surgery: a population-based, observational study
Johan Bjellvi, Sweden

Memory performance after stereotactic radiofrequency amygdalohippocampectomy – five years follow up
Lenka Kramská, Czech Republic

11:30 – 13:00  Epilepsy syndromes

Co-chair: Michael Kerr, United Kingdom
Co-chair: Vasilios Kimiskidis, Greece

Expert consensus for the diagnosis of Dravet syndrome
Elaine Wirrell, USA

West syndrome: electroclinical and etiological aspects about 93 patients followed in Senegal
Fidelie Scholastique N’Goungoue Halima, Senegal

Investigation of clinical and EEG features in patients with genetic generalized epilepsy presenting with eyelid myoclonia
Güney Altıokka Uzun, Turkey

Clinical and electroencephalographic characterization of myoclonic epilepsy with photosensitivity in juvenile pure-bred dogs
Franziska Wielaender, Germany

Limbic encephalitis in late-onset partial epilepsies: a prospective, population-based study
Felix von Podewils, Germany

Epilepsy and its treatment in Nicolaides-Baraitser syndrome
Gerhard Kluger, Germany
SCIENTIFIC PROGRAMME  

WEDNESDAY 14TH SEPTEMBER 2016

PLATFORM SESSION
Panorama Hall

11:30 – 13:00

Basic science 3

Co-chair: Marco de Curtis, Italy
Co-chair: Annamaria Vezzani, Italy

Disulfide HMGB1 is generated by oxidative stress in the rat hippocampus during epileptogenesis and represents a novel mechanism of disease onset and progression
Annamaria Vezzani, Italy

Neuronal auto-antibodies in mesial temporal lobe epilepsy with hippocampal sclerosis: epiphenomenon or marker for an autoimmune subtype?
Ebru Nur Vanli-Yavuz, Turkey

Biomarkers of blood-brain barrier damage and their association with disease activity in patients with chronic epilepsy
Elzbieta Bronisz, Poland

Macro and microglial activation in the eye following epileptic seizures
Matilda Ahl, Sweden

Beta and gamma suppression of background EEG predicts brain injury and subsequent epilepsy in a rat model of perinatal hypoxia-ischemia
F.E. Dudek, USA

Non-invasive detection of fast ripples in low-noise EEG recordings
Ece Boran, Switzerland

PARALLEL SESSION
Meeting Hall V

11:30 – 13:00

Classification of the epilepsies

Co-chair: Sameer Zuberi, United Kingdom
Co-chair: Emilio Perucca, Italy

The framework for the new classification of the epilepsies
Ingrid Scheffer, Australia

Summary of online feedback
Sameer Zuberi, United Kingdom

Panel discussion
Emilio Perucca, Italy
Ingrid Scheffer, Australia
Sameer Zuberi, United Kingdom

PARALLEL SESSION
Forum Hall

14:30 – 16:00

The life cycle of antiepileptic drugs

Co-chair: Torbjörn Tomson, Sweden
Co-chair: Heinz Beck, Germany

Pitfalls of preclinical studies: a tale of networks and power
Heinz Beck, Germany

Pitfalls of clinical studies
Jacqueline French, USA

Pitfalls during and after approval of antiepileptic drugs
Hajo Hamer, Germany
SCIENTIFIC PROGRAMME  WEDNESDAY 14TH SEPTEMBER 2016

PARALLEL SESSION  South Hall

14:30 – 16:00

Seizures and stroke: from bad to worse and what could be done about it?

Chair: Ivan Rektor, Czech Republic

A devastating outcome of the devastating disease: implications for patients and burden for the society
Alla Guekht, Russian Federation

Seizures after stroke. Can we predict?
Mini Neufeld, Israel

Stroke after seizures
Eugen Trinka, Austria

Seizures after stroke. Can we prevent?
Felix Rosenow, Germany

SCIENTIFIC PROGRAMME  WEDNESDAY 14TH SEPTEMBER 2016

SPECIAL SYMPOSIUM  Meeting Hall I

14:30 – 16:00

Neurostimulation in epilepsy – a joint CEA–EAN Symposium

Co-chair Christoph Baumgartner, Austria
Co-chair Kristl Vonck, Belgium

Neurostimulation in neurology
Paul Boon, Belgium

Basic biophysical principles of neurostimulation
Wytsje Wadman, Netherlands

Non invasive neurostimulation
Christoph Baumgartner, Austria

Neurostimulation in epilepsy – what have we achieved and where should we go?
Andreas Schulze-Bonhage, Germany

PARALLEL SESSION  Panorama Hall

14:30 – 16:00

Inhibition synchronization ahead of seizures – protective or harmful?

Co-chair Marco de Curtis, Italy
Co-chair Roberto Spreatico, Italy

Ictal onset and inhibitory networks: inhibition precipitates seizures
Massimo Avoli, Canada

The concept of seizure penumbra: inhibition protects against seizures
Andrew Trevelyan, United Kingdom

Optogenetic challenge of inhibitory networks and ictogenesis
Merab Kokaia, Sweden

GABAergic neurons in human epileptic networks
Roberto Spreatico, Italy
**SCIENTIFIC PROGRAMME**

**WEDNESDAY 14TH SEPTEMBER 2016**

**SPECIAL SYMPOSIUM**
Meeting Hall V

14:30 – 16:30

**Symposium of Excellence in Epileptology**

Co-chair: Meir Bialer, Israel
Co-chair: Martin Brodie, United Kingdom

**Why is immature brain prone to seizures?**
Pavel Mareš, Czech Republic

**The spectrum of benign infantile seizures**
Federico Vigevano, Italy

**Fast oscillations and fast imaging – new ways of understanding epileptic networks**
Julia Jacobs, Germany

**Epileptic encephalopathies: clues for future diagnosis and management**
Nicola Specchio, Italy

**Anatomo-electro-clinical reasoning in epilepsy surgery**
The 2016 Epileptic Disorders-ILAE Educational Award
Ioana Mindruta, Romania

**SATELLITE SYMPOSIUM**
Forum Hall

16:30 – 18:00

Please see page 102 for full details on the satellite symposium

**PARALLEL SESSION**
South Hall

16:30 – 18:00

**Mendel’s Symposium – Molecular genetic testing in epilepsies, anno 2016: an essential diagnostic tool**

Co-chair: Peter De Jonghe, Belgium
Co-chair: Vladimír Komárek, Czech Republic

**Molecular diagnosis in genetic epilepsies: complexity, needs, tools and opportunities**
Sarah Weckhuysen, Belgium

**Next generation sequencing with gene panels: a revolution in molecular diagnostics**
Johannes Lemke, Germany

**Whole Exome Sequencing (WES) in diagnostics; the new kid on the block**
Heather Mefford, USA

**Copy number variants: now easy to detect but still difficult to interpret**
Ingo Helbig, Germany
12th European Congress on Epileptology

SCIENTIFIC PROGRAMME

WEDNESDAY 14TH SEPTEMBER 2016

PARALLEL SESSION
Meeting Hall I

16:30 – 18:00

Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery

Co-chair: Ylva Østby, Norway
Co-chair: Miri Neufeld, Israel

In search of memory networks in TLE – new evidence and opportunities using fMRI
Mary Pat McAndrews, Canada

Localization/lateralization diagnostics and its value for monitoring of the course and the surgical treatment of TLE
Christoph Helmstaedter, Germany

Memory and the brain in temporal lobe epilepsy – integrating basic science and clinical perspectives in epilepsy surgery
Ylva Østby, Norway

PARALLEL SESSION
Panorama Hall

16:30 – 18:00

Genetic (idiopathic) focal epilepsies with sleep activation – “benign” no more?

Co-chair: Edouard Hirsch, France
Co-chair: Helen Cross, United Kingdom

Rolandic epilepsy to epilepsy with CSWS via Landau-Kleffner syndrome: one syndrome or many?
Eliane Roulet-Perez, Switzerland

Insights into neuropsychological impairments from functional neuroimaging
Patrick Van Bogaert, Belgium

Can molecular genetics reveal mechanisms and novel targets for therapy?
Pierre Szepetowski, France

The evidence base for pharmacological therapy & treatment paradigms
Floor Jansen, Netherlands
**SCIENTIFIC PROGRAMME**

**WEDNESDAY 14TH SEPTEMBER 2016**

**PARALLEL SESSION**
Meeting Hall V

16:30 – 18:00  
**The neurobiology of Focal Cortical Dysplasias (FCD) – new genes, mechanisms and diagnostic tools**

*Co-chair: Ingmar Blümcke, Germany  
Co-chair: Betül Baykan, Turkey*

**The genetics of FCD**
Jamel Chelly, France

**Epigenetic biomarkers in FCD**
Katja Kobow, Germany

**New diagnostic tools in FCD (clinical)**
Roberto Spreafico, Italy

**New challenges in FCD: molecular mechanisms of epileptogenesis**
Eleonora Aronica, Netherlands

**EGE FORUM**
Forum Hall

18:15 – 19:45  
**Epilepsy management in countries with limited resources – current state and future perspectives**

*Co-chair: Silvio Basic, Croatia  
Co-chair: Alla Guekht, Russian Federation*

**Pharmacoresistant epilepsy – diagnostic and therapeutic challenge in countries with limited resources**
Joanna Jędrzejczak, Poland

**How to build up and run a video-EEG monitoring unit**
Eugen Trinka, Austria

**Establishing invasive EEG monitoring (SEEG) in countries with limited resources – our eight year experience**
Silvio Basic, Croatia

**Advanced techniques in epilepsy surgery with limited resources – neurosurgical point of view**
Darko Chudy, Croatia

**Panel Discussion (all speakers and chairs): Treating epilepsy in countries with limited resources**
**Scientific Programme**  
**Wednesday 14th September 2016**

**ECE Forum**  
South Hall

**18:15 – 19:45**  
*When epilepsy sets in – your (personal/family) life*

*Chair: David Gosar, Slovenia*

*Video, short questionnaire, panel discussion, roundtable, open discussion*

Stéphane Auvin, France  
David Gosar, Slovenia  
Petra Musek, Slovenia  
Vesna Krkoč, Slovenia  
Daša Kočjančič, Slovenia  
Ljubica Vrba, Slovenia  
Latica Friedrich, Croatia  
Gal Grandal, Slovenia  
Reetta Kalviainen, Finland

**ECE Forum**  
Meeting Hall I

**18:15 – 19:45**  
*What is SHE (Sleep-related Hypermotor Epilepsy)? Epileptologists meet sleep experts*

*Co-chair Paolo Tinuper, Italy  
Co-chair Andreas Schulze-Bonhage, Germany*

*The history of SHE, a new syndrome aged 35 years*  
Francesca Bisulli, Italy

*Looking around (outside of) the frontal lobes*  
Philippe Kahane, France

*Etiology of SHE: genetic, lesional and the blurring boundary*  
Ingrid Scheffer, Australia

*Discussion with the experts in sleep medicine at the European Sleep Research Society Congress in Bologna*  
Coordinator: Lino Nobili, Italy
**SCIENTIFIC PROGRAMME**

**WEDNESDAY 14TH SEPTEMBER 2016**

**PLATFORM SESSION**
Panorama Hall

18:15 – 19:45

**Prognosis and outcome**

*Co-chair: Renzo Guerrini, Italy
Co-chair: Eva Kumlien, Sweden*

**Outcomes of West syndrome treatment at the long-term follow-up**
Rimma Gamirova, Russian Federation

**Long-term prognosis of adolescent-onset idiopathic generalised epilepsies**
Bernd J Vorderwülbecke, Germany

**Epilepsy with auditory features (EAF): long-term outcome in a large cohort**
Veronica Menghi, Italy

**Post-stroke epilepsy and stroke recurrence in long-term follow-up after ischemic stroke**
Petra Redfors, Sweden

**Poststroke epilepsy in Sweden: a population-based registry study**
Johan Zelano, Sweden

**VNS in patients with drug resistant epilepsy: younger age at implantation may result in better efficacy**
Zvonka Rener-Primec, Slovenia

---

**SCIENTIFIC PROGRAMME**

**WEDNESDAY 14TH SEPTEMBER 2016**

**PLATFORM SESSION**
Meeting Hall V

18:15 – 19:45

**Varia**

*Co-chair: David Krysl, Czech Republic
Co-chair: Stefano Meletti, Italy*

**Ictal dystonic posturing with tremor and ipsilateral tonic leg extension after the figure of four sign – new lateralizing and localizing semio logic signs**
Gudrun Kalss, Austria

**Motor phenomena in vasovagal syncope: clinical aspects and comparison with convulsive seizures**
Sharon Shmueli, Netherlands

**Preliminary results of a systematic review on diagnostic accuracy and clinical value of long term video-EEG monitoring in non-invasive presurgical evaluation of patients with epilepsy**
Tela Kobulashvili, Austria

**Poly somnographic based study of sleep in juvenile myoclonic epilepsy patients**
Sonia Elbhravy, Egypt

**Late breaking abstract**
TBC

**Holistic application of new technology to the management of epilepsy: The epilepsy networks project**
Rupert Page, United Kingdom
**THURSDAY 15TH SEPTEMBER 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Forum Hall</th>
<th>South Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>Déjà vu phenomenon – physiologic or pathologic?</td>
<td>Increasing Participation in Clinical Research in Epilepsy</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.30-09.00</td>
<td>Large scale brain networks in epilepsy</td>
<td>Understanding epilepsy through glia</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Taking a fresh look at excitation / inhibition (im)balance and its role in seizure generation</td>
<td>Social cognition in epilepsy patients</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Congress Highlights Session</td>
<td></td>
</tr>
<tr>
<td>13.00-13.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-14.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ECE FORUM
Forum Hall

07:30 – 09:00  Déjà vu phenomenon – physiologic or pathologic?

Co-chair: Antonio Gambardella, Italy
Co-chair: Milan Brázdil, Czech Republic

Presentations and Panel Discussion
Milan Brázdil, Czech Republic
Adam Zeman, United Kingdom
Angelo Labate, Italy

ECE FORUM
South Hall

07:30 – 09:00  Increasing participation in clinical research in epilepsy

Co-chair: Peter Bergin, New Zealand
Co-chair: Merab Kokaia, Sweden

Interactive Workshop
Peter Bergin, New Zealand
Ettore Beghi, Italy
Jeremy Jost, France
Tony Marson, United Kingdom

ECE FORUM
Meeting Hall I

07:30 – 09:00  Young investigators forum – Neurovascular alterations in epilepsy

Co-chair: Erwin van Vliet, Netherlands
Co-chair: Nicola Marchi, USA

Perivascular inflammation and anti-inflammatory treatment
Teresa Ravizza, Italy

Vascular alterations after traumatic brain injury
Xavier Ekolle N'do N'dike, Finland

Role of pericytes in cerebrovascular remodeling and epilepsy
Nicola Marchi, USA

mTOR inhibition to restore blood-brain barrier leakage in epilepsy
Erwin van Vliet, Netherlands

Losartan prevents acquired epilepsy via TGF-β signaling suppression
Guy Bar-Klein, Israel
THURSDAY 15TH SEPTEMBER 2016

TEACHING COURSE
Panorama Hall

08:00 – 10:00
EEG Technician Course

Co-chair: Jana Zarubova, Czech Republic
Co-chair: Christian Skaarup, Denmark

Activation methods during EEG – benefits, risks
Irena Doležalová, Czech Republic
Petr Zlonicky, Czech Republic

Safety in epilepsy monitoring unit and role of technicians
Gudrun Kals, Austria

Artifacts – tips and tricks to avoid them
Christian Skaarup, Denmark

Ambulatory electroencephalography and home video-EEG monitoring
Franz Brunnhuber, United Kingdom

08:00 – 12:30
Epileptology in the ICU

Co-chair: Eugen Trinka, Austria
Co-chair: Andrea Rossetti, Switzerland

Definition, classification, and incidence of status epilepticus
Eugen Trinka, Austria

EEG features and differential diagnosis of status epilepticus
Vincent Navarro, France

Treatment of status epilepticus
Felix Rosenow, Germany

Clinical neurophysiology for the prognosis of postanoxic coma
Andrea Rossetti, Switzerland

The ACNS EEG nomenclature: usefulness and limits
Nicolas Gaspard, Belgium
09:00 – 10:30

**Large scale brain networks in epilepsy**

*Co-chair: Maxime Guye, France*
*Co-chair: Serge Vulliemoz, Switzerland*

**Contribution of network structure and dynamics to EEG-based diagnosis of epilepsy**
Mark Richardson, United Kingdom

**The role of the relation between cognition and large scale networks in focal epilepsies**
Ivan Rektor, Czech Republic

**Can we define specific properties of epileptogenic networks by studying large-scale networks during interictal state?**
Maxime Guye, France

09:00 – 10:30

**Understanding epilepsy through glia**

*Co-chair: Christian Steinhäuser, Germany*
*Co-chair: Pavel Mares, Czech Republic*

**A new mouse model of mesial temporal lobe epilepsy to identify the role of activated microglia and dysfunctional astrocytes in early epileptogenesis**
Peter Bedner, Germany

**Optogenetic analysis of astrocyte gliotransmission in the healthy and epileptic hippocampus of the mouse**
Etienne Audinat, France

**Abnormal astrocytic Ca2+ signalling in the sclerotic hippocampus of awake mice: two-photon imaging using the unilateral intracortical kainate model of mesial temporal lobe epilepsy**
Kjell Heuser, Norway

**The relationship between seizure activity per se and neuroinflammation: specific glial molecule expression in the intrahippocampal kainate model and in human dysplasias**
Marco de Curtis, Italy
Rita Garbelli, Italy

**Experimental considerations for in vivo Ca2+ imaging in animal models of epilepsy**
Frank Kirchhoff, Germany

**The pros and cons of a brain slice model to investigate the role of astrocytes in acute focal seizures**
Giorgio Carmignoto, Italy
SCIENTIFIC PROGRAMME  THURSDAY 15TH SEPTEMBER 2016

ECF FORUM  Meeting Hall I

09:00 – 10:30  Epileptic encephalopathies: old and new treatment strategies
Co-chair: Federico Vigevano, Italy  
Co-chair: Petia Dimova, Bulgaria

Epileptic encephalopathy versus encephalopathy with epilepsy
Nicola Specchio, Italy

From diagnosis to standard therapeutic approach
Federico Vigevano, Italy

Alternative treatments in epileptic encephalopathies
Stéphane Auvin, France

Epilepsy surgery and neuromodulation
Petia Dimova, Bulgaria

SCIENTIFIC PROGRAMME  THURSDAY 15TH SEPTEMBER 2016

TEACHING COURSE  Panorama Hall

10:30 – 12:30  Pharmacological aspects of antiepileptic drugs (AEDs)
Co-chair: Svein Johannessen, Norway
Co-chair: Hana Kubová, Czech Republic

What is the best mechanism of action for optimal response and tolerability?
Hana Kubová, Czech Republic

Can we hope for newer and better antiepileptic drugs?
Meir Bialer, Israel

Is pharmacokinetic variability of clinical importance?
Cecilie Johannessen Landmark, Norway

Can pharmacokinetic variability be controlled for patients’ benefit?
Svein Johannessen, Norway
SCIENTIFIC PROGRAMME

THURSDAY 15TH SEPTEMBER 2016

ECE FORUM
Forum Hall

11:00 – 12:30

Taking a fresh look at excitation / inhibition (im)balance and its role in seizure generation. A pro and contra debate

Co-chair: Rüdiger Köhling, Germany
Co-chair: Massimo Avoli, Canada

Pro inhibition: Inhibitory activity and seizure initiation
Marco de Curtis, Italy

Pro excitation: And what about excitation? Is there still a role for the excitation-inhibition imbalance, or do we have to rephrase it?
Gilles Huberfeld, France

Pro inhibition? Optogenetic modulation of chloride using optogenetics: an approach to tackle seizures?
Andrew Trevelyan, United Kingdom

Pro excitation? Taking a new look at an old acquaintance: role of potassium in seizure generation
Massimo Avoli, Canada

ECE FORUM
South Hall

11:00 – 12:30

Social cognition in epilepsy patients

Co-chair: Hrvoje Hecimovic, Croatia
Co-chair: Petr Marusic, Czech Republic

Presentations & Panel Discussion
Bettina Steiger, Switzerland
Stefano Meletti, Italy
Jana Amlerova, Czech Republic
Hrvoje Hecimovic, Croatia

ECE FORUM
Meeting Hall I

11:00 – 12:30

“Epilepsy is more than seizures”: psychiatric disorders in epileptic encephalopathies, an underdiagnosed condition

Co-chair: Rima Nabbout, France
Co-chair: Nicola Specchio, Italy

Series presentation (DS/PCDH19/TSC) and general panel discussion
Lisa Ouss, France
Nicola Specchio, Italy
Elisabeth Thiele, USA

HIGHLIGHTS SESSION
Forum Hall

12:30 – 13:30

Highlights Session

Co-chair: Meir Bialer, Israel
Co-chair: Milan Brázdil, Czech Republic

Pharmacology highlights
Christian Elger, Germany

Basic science highlights
Hana Kubová Czech Republic

Surgery highlights
Margitta Seeck, Switzerland

Paediatric highlights
Sameer Zuberi, United Kingdom
SATELLITE SYMPOSIA

SUNDAY 11TH SEPTEMBER

Satellite Symposium
Meeting Hall I

16:30 – 18:00  LivaNova: SUDEP and mortality – expect the unexpected

Chair: Philippe Ryvlin, Switzerland

Introduction – expect the unexpected
Philippe Ryvlin, Switzerland

SUDEP – epidemiology & pathophysiology
Torbjörn Tomson, Sweden

Roadmap to prevention – Seizure Detection & Biomarkers
Orrin Devinsky, USA

VNS therapy & SUDEP
Philippe Ryvlin, Switzerland

MONDAY 12TH SEPTEMBER

Satellite Symposium
Meeting Hall I

07:30 – 09:00  Zogenix Incorporated: understanding the biology and treating early-onset epileptic encephalopathies (EEs): how will evolving science shape future treatments?

Co-chair: Joseph Sullivan, USA
Co-chair: Lieven Lagae, Belgium

Basic science and preclinical models of EEs – improving the construct, face, and predictive validity of current models in the search for new treatment options
Ben Whalley, United Kingdom

The evolving and critically important role of genetics in EEs
Rima Nabbout, France

Early-onset EE management – might treatment change as the science evolves?
Tilman Polster, Germany

Satellite Symposium
Forum Hall

16:30 – 18:00  Elekta: Magnetoencephalography: a useful tool in the clinical practice

Chair: Paul Boon, Belgium

Value of MEG in clinical neurology
Evelien Carrette, Belgium

MEG and high-density EEG: is it useful or diagnostic overkill?
Hermann Stefan, Germany

Source montages: scanning the MEG for spikes in source space
Sándor Beniczky, Denmark
TUESDAY 13TH SEPTEMBER

Satellite Symposium
Panorama Hall

07:30 – 09:00 EISAI Europe: Reflections on the AMPA receptor as a target in epilepsy
Chair: Matthew Walker, United Kingdom

AMPA receptors in seizure pathophysiology
Matthew Walker, United Kingdom

Spotlight on AMPA receptors in focal seizures associated with brain tumours
Antonietta Coppola, United Kingdom

Focus on the patient: applying knowledge to clinical decision-making
Mar Carreño, Spain

Discussion with Q&A

Satellite Symposium
Forum Hall

16:30 – 18:00 Eisai and Bial – Portela & C* S.A.: Optimising Epilepsy Monotherapy: unmasking the smoke & mirrors
Chair: Martin Holtkamp, Germany

The US conversion to monotherapy trials
Jacqueline French, USA

The EU non-inferiority monotherapy trials
Eugen Trinka, Austria

Discussion with the active participation from the audience, moderated by the chairman
Martin Holtkamp, Germany

WEDNESDAY 14TH SEPTEMBER

Satellite Symposium
Panorama Hall

07:30 – 09:00 EISAI Europe: Debating the impact of AEDs on behavioural change and cognitive impairment in epilepsy
Chair: Mar Carreño, Spain

DEBATE 1: Should behavioural and psychiatric side effects limit our use of AEDs?
Martin Brodie, United Kingdom
Matthew Walker, United Kingdom

DEBATE 2: Are cognitive impairments in patients with epilepsy caused primarily by AEDs?
Lieven Lagae, Belgium
Christoph Helmstaedter, Germany

Discussion and Q&A. Moderated by the chair, with participation from all speakers
Mar Carreño, Spain
WEDNESDAY 14TH SEPTEMBER

Satellite Symposium
Forum Hall

16:30 – 18:00  
**EISAI Europe: Lessons from the clinic: What have we learned from real-world use?**

*Chair: Milan Brázdíl, Czech Republic*

- **Clinical experience from large cohorts**
  Eugen Trinka, Austria

- **Real-world evidence in special sub-populations**
  Bertrand de Toffol, France

- **Putting real-world data into practice: case studies in idiopathic generalised epilepsies**
  José Serratosa, Spain

- **My perspective: The patient voice**
  Patient speaker

- **Conclusions and Q&A**
POSTERS INFORMATION

Posters are exhibited in the Forum Hall Foyer, situated on the second floor of the congress centre directly above the Registration Area. Posters are on display from 10:00 to 17:00, Monday to Wednesday, with different posters presented each day. Poster presenters are required to set up their posters between 09:00 and 10:00 each morning. Posters must be removed each evening between 17:00 and 18:00.

The poster abstracts are available on the 12th ECE website www.epilepsyprague2016.org in the interactive session planner. Full abstracts, including the authors’ list and affiliations, will be published in an Epilepsia online supplement post-congress.

Delegates can search for abstracts by keywords and access the full papers on the Congress App which can be downloaded from the App Store on your device.

POSTER TOURS

The International Scientific and Organising Committee has chosen to organise guided poster tours (led by experts in the field) giving researchers the opportunity to present their work during the congress. Presenters will be available at their posters on their assigned day. Each presenter shall be given three minutes to outline their findings and answer questions.

Guided poster tours will start at 13:00, Monday – Wednesday, from the first poster listed in each tour.

Please note that abstracts number 001 to 106 have been selected for platform presentation.

MONDAY 12TH SEPTEMBER

13:00 – 14:30 BASIC SCIENCE 1

P107 Comparison of tyrosine hyroxylase immunoreactivity in substantia nigra pars compacta between gaers and wistar rats
Ozlem Akman, Turkey

P108 The myelin mutant taiep rat as a model of absence epilepsy
Jose Eguibar, Mexico

P109 Effect of external perturbations on seizure dynamics – in vitro results and computational modelling
Jaroslav Hlinka, Czech Republic

P110 A new rat model of infantile spasms based on methylazoxylmethanol (MAM)-induced cortical dysplasia
Eun-Hee Kim, Korea, Republic of

P111 Aliskiren, a direct renin inhibitor, protects against pentylentetrazole-induced seizures in mice
Krzysztof Łukawski, Poland

P112 Effect of GABA-B drugs on seizures and motor performance in immature rats
Pavel Mareš, Czech Republic

P113 Somatostatin immunoreactive interneurons survival in the intrahippocampal kainite model. A model characterization
Esbjörn Melin, Sweden

P114 A new rat model of sustained cortical spike-and-wave seizures
Cristian Sevcencu, Denmark

P115 Acute electrophysiological changes induced by cortical photochemical ischemia in adult rat
Jan Svoboda, Czech Republic

P116 Computational assessment of hippocampal sclerosis in mesial temporal lobe epilepsy
Anna Maria Toeglhofer, Austria

P117 Neurochemical changes in the endothelin-1 model of focal cerebral ischemia in immature rats
Kateřina Vondráková, Czech Republic
MONDAY 12TH SEPTEMBER

13:00 – 14:30 BASIC SCIENCE 2

P118 Training in novelty exploration tasks prevents cognitive decline in a rat model of temporal lobe epilepsy
Ángela Amaro-Leal, Portugal

P119 Aberrant neuronal activity and behavior is underlined by the loss of constitutive androstane receptor
Badreddine Boussadia, France

P120 The peculiarities of epileptiform activity formation in rats during subconvulsive doses picrotoxin and pentylenetetrazole repetitive injections
Oksana Viktorovna Denysenko, Ukraine

P121 Antiepileptic potential of K+-channels in acute and chronic models of epilepsy
Rüdiger Köhling, Germany

P122 Do seizures effect cerebral uptake mechanisms for essential compounds? Preliminary results from rat lithium pilocarpine model
Aniv Mann, Israel

P123 Analysis of HFOs during microseizures in humans with epilepsy
Eva Martínez-Lizana, Spain

P124 Differential epileptiform activity results in disparate responses in interneurons
R Ryley Parrish, United Kingdom

P125 The progression of EEG abnormalities during epileptogenesis after lateral fluid percussion injury
Aylin Reid, Canada

P126 Chronic deficiency in the brain energy supply is a triggering mechanism in the early stage of epileptogenesis
Evgeniia Samokhina, Russian Federation

P127 Uncomplete recovery from Mg2+ suppression of nonsynaptic epileptiform activity on an invertebrate model system
Marija Stanojević, Serbia

P128 A novel focal seizure pattern associated with blockade of synaptic transmission
Laura Uva, Italy

MONDAY 12TH SEPTEMBER

13:00 – 14:30 CLINICAL EPILEPSY 1

P170 Prevalence and clinical characteristic of childhood-onset frontal lobe epilepsy in Algiers
Walid Abdellaoui, Algeria

P171 Diagnostic text database on Android OS tablet personal computer which contains the typological classification of motor, sensory, autonomic, cognitive, psychic paroxysmal symptoms and their related seizures/syndromes with algorithm based on symbolic logical duality and intersection of common syndrome
Vladimir Andreev, Russian Federation

P172 Evaluation of 11 cases with epileptic nystagmus
Ibrahim Aydogdu, Turkey

P173 Complex and non-stereotyped visual hallucinations as symptoms of acute symptomatic crises
Paolo Benna, Italy

P174 Use of the DISCOVER form (a structured diagnostic interview) to ensure correct classification in a study of disease impact
Jacqueline French, USA

P175 Prone sleeping and SUDEP risk: the dynamics of body positions in non-fatal convulsive seizures
Sharon Shmuely, Netherlands

P176 Classification and therapeutic outcome in 96 cases with Sturge-Weber syndrome
Hiroharu Suzuki, Japan

P177 Using random forest for diagnosis and lateralization of temporal lobe epilepsy from EEG-based directed functional connectivity
Pieter van Mierlo, Belgium

P178 Non-convulsive status epilepticus in children and young adults at a residential epilepsy centre
Daniel Yusef, United Kingdom
MONDAY 12TH SEPTEMBER

13:00 – 14:30  CLINICAL EPILEPSY 2

P179  Superficial hemosiderosis of the central nervous system: a rare cause of epilepsy
Filip Derke, Croatia

P180  Antiepileptic drug treatment in elderly patients with epilepsy
Revital Gandelman-Marton, Israel

P181  Sleep-changes and epilepsy in Alzheimer’s: causes or complications?
András Horváth, Hungary

P182  Clinical features and prognosis of epilepsy in the elderly in western China
Cheng Huang, China

P183  Lacosamide as conversion to monotherapy in older adults with epilepsy: a retrospective study
Francesca Izzi, Italy

P184  Acute symptomatic seizures and epilepsy in stroke patients; etiological subtypes and clinical characteristics
Petr Jansky, Czech Republic

P185  Status epilepticus in the elderly patients: a national data study in Thailand
Somsak Tiamkao, Thailand

MONDAY 12TH SEPTEMBER

13:00 – 14:30  CLINICAL NEUROPHYSIOLOGY 1

P222  Blink reflex studies in genetic generalized epilepsy patients with eyelid myoclonia
Gunes Altıokka Uzun, Turkey

P223  Added value of the inferior temporal electrode chain in the identification of EEG abnormalities
Sándor Beniczky, Denmark

P224  Afternoon NAP versus all-night sleep EEG for the diagnosis of ESES
Elena Gardella, Denmark

P225  Changes in cardiovascular autonomic function in patients with newly diagnosed epilepsy
Rajesh Kumar Goit, Nepal

P226  Single calcified neurocysticercosis lesion as a true Pediatric epilepsy substrate in endemic regions: a prevalence and clinico-electroencephalographic-anatomical correlation study
Rachana Dubey, India

P227  Caffeine maintains arousal level and prevents change of electroencephalogram spectra powers
Howon Lee, Korea, Republic of

P228  Chloralhydrate is more effective than melatonin in inducing sleep for sleep-deprived children undergoing paediatric EEG
Hian-Tat Ong, Singapore

P229  A pilot study of ambulatory home video telemetry (AHVT) in adults at St Thomas’ Hospital, London
Joanne M Pauline, United Kingdom

P230  Automated classification of epileptic spikes in iEEG recorded during fMRI acquisition for improved BOLD modelling
Niraj Sharma, United Kingdom
MONDAY 12TH SEPTEMBER

13:00 – 14:30  CLINICAL NEUROPHYSIOLOGY 2

P231 Coherent analysis of interconnections in the drug-resistant multifocal epilepsy pathologic system
Michael Alexandrov, Russian Federation

P232 Contribution of video-electroencephalography in the study of non-epileptic psychogenic seizures
Fatoumata Ba, Senegal

P233 Framework for introducing high-frequency oscillation analysis into clinical decision making process
Jan Cimbalník, Czech Republic

P234 Convenient and portable subcutaneous EEG monitor for ultra-long term out-patient use
Jonas Duun-Henriksen, Denmark

P235 Detection of epileptic seizures using phase–amplitude coupling in intracranial electroencephalography
Kohtaroh Edakawa, Japan

P236 Electroencephalogram findings in patients with uremic encephalopathy
Dragica Milikic, Montenegro

P237 Electro-clinical features of Video-EEG recorded seizures in 51 patients with TSC related epilepsy
Alessia Mingarelli, Italy

P238 Differentiating epileptic from non-epileptic high frequency iEEG signals using wavelet entropy
Anne H Mooij, Canada

P239 Epilepsy and sleep apnea: comorbidity or related disorder?
Natela Okujava, Georgia

P240 Frequency domain connectivity patterns in EEG focal and generalized interictal epileptogenic discharges and its relation to 3-D spike source analysis
Alberto Pinzon, USA

P241 Electroclinical features of epilepsy associated with SYNGAP1 mutation
Vasiliki Tsirka, United Kingdom

MONDAY 12TH SEPTEMBER

13:00 – 14:30  EPILEPSY IN CHILDHOOD 1

P262 Periventricular nodular heterotopia and epileptic seizures
Eleni Alexiou, Greece

P263 Stereo-EEG recording, radiofrequency thermocoagulation and neuropathologic correlations in a patient with MRI negative type IIb focal cortical dysplasia
Rita Garbelli, Italy

P264 Early seizures in patient with acute stroke in Kosovo
Valbona Govori, Albania

P265 Electroencephalographic markers of preictal disorders
Marina Korsakova, Russian Federation

P266 Electroencephalographic change of non-affected side of hemimegalencephaly and developmental progress after hemispherotomy
Eiji Nakagawa, Japan

P267 The role of cerebral imaging in diagnosing a rare case of electro-clinically silent tuberous sclerosis
Smaranda Antonia Nita, Romania

P268 Anti-epileptic treatment of five adult institutionalized patients with subcortical band heterotopia due to DCX mutations: a 20-year follow-up
Helenius Jurgen Schelhaas, Netherlands

P269 Focal cortical dysplasia associated to brain tumor (FCD Type IIIb according the ILAE). Clinic, pathological and immunohistochemistry approaches.
Running head: focal cortical dysplasia associated to brain tumor
Martha Lilia Tena Suck, Mexico

P270 Focal cortical dysplasia associated with cavernoma (FDC Type IIIc according the ILAE). Clinical, histopathology and immunohistochemistry correlation
Salvador Vergara Lopez, Mexico
MONDAY 12TH SEPTEMBER

13:00 – 14:30  
**EPILEPSY IN CHILDHOOD 2**

P296  
A new homozygous mutation on NPC2 gene: as a cause of refractory epilepsy in a child  
Kürşad Aydın, Turkey

P297  
Antiphospholipid antibodies in children with epilepsy  
Cornelia Calcii, Moldova, Republic of

P298  
Genetic syndromes in children with epileptic encephalopathy  
Maria Fomina, Russian Federation

P299  
Serum trace element levels in children with epilepsy; an observational study  
Sheffali Gulati, India

P300  
Hippocampal neurogenesis after seizures: a role in development of chronic epilepsy  
Ayushi Jain, India

P301  
Evaluation of cognitive and behavioral functions in children of epileptic mothers  
Nirmeen Kishk, Egypt

P302  
Etiology of convulsive and nonconvulsive seizures in patients with severe TBI  
Olga Kochetkova, Russian Federation

P303  
A refractory epilepsy case with ictal asystole  
Leman Tekin Orgun, Turkey

P304  
A rare form of seizure: epileptic nystagmus  
Leman Tekin Orgun, Turkey

---

MONDAY 12TH SEPTEMBER

13:00 – 14:30  
**EPILEPSY IN CHILDHOOD 3**

P305  
Children and adolescents with neurofibromatosis type 1 without epilepsy—how useful are EEG and MRI?  
Bora Cekic, Serbia

P306  
BDNF in children with epilepsy  
Svetlana Hadjiu, Moldova, Republic of

P307  
Behavioral disturbances in children with epilepsy  
Svetlana Hadjiu, Moldova, Republic of

P308  
Correction of cognitive deficiency in children having cerebral palsy with symptomatic epilepsy  
Tatiana Kazennykh, Russian Federation

P309  
Characteristics of Polish paediatric patients with early and late post-stroke seizures  
Ilona Kopyta, Poland

P310  
Crohn’s disease associated with focal epilepsy and neuroimaging findings of hippocampal sclerosis and cerebral hemiatrophy  
Kelin Cristine Martin, Brazil

P311  
Comparison of Polish paediatric patients with and without diagnosed post-stroke epilepsy  
Beata Sarecka-Hujar, Poland

P312  
Case report with autoimun epilepsy  
Aferdita Tako Kumaraku, Albania

P313  
Initial treatment of epileptic disintegrative disorders in children  
Dmitry Zaytsev, Russian Federation
P358  Epilepsy, cutis verticis gyrata, dysphagia, severe intellectual disability, and other features: a new epilepsy syndrome?
Simona Balestrini, United Kingdom

P314  Epilepsy in young Tsc1+/- mice exhibits age-dependent expression mimicking that of human tuberous sclerosis complex
Svetlana Gataullina, France

P315  Electroencephalogram requests in paediatrics: are paediatricians following NICE (National Institute of Clinical Excellence) guidance?
Eleanor Glenday, United Kingdom

P316  Etiology and clinical characteristics of seizures in the first year of life treated in tertiary center: a cohort of 127 infants
Miljana Grkinic Jovanovic, Serbia

P317  Epidemiology of epilepsy in pediatric population in Zabaikalsky Krai
Natalia Marueva, Russian Federation

P318  Encephalitis associated with GABAA-R autoantibodies in a child: long-term outcome and therapeutic challenges
Giorgia Olivieri, Italy

P319  ESES – “The stranger with many faces”: our clinical experience
Eugenia Roza, Romania

P320  Epilepsy after stroke in children
Inna Shchederkina, Russian Federation

P321  Epilepsy with myoclonic atonic seizures in a seven-years old child with ischemic cerebral stroke – a consequence or a parallel condition?
Gabriela Tavchioska, Macedonia, the Former Yugoslav Republic of

P365  Clinical and neurophysiological features of patients with PCDH19-related epilepsy
Katrin Bamdeg, Denmark

P366  A novel FARS2 mutation in familial cases of early onset epileptic encephalopathy
Jae So Cho, Korea, Republic of

P367  De novo mutations of KIAA2022 in females cause intellectual disability and intractable epilepsy
Iris De Lange, Netherlands

P368  Congenital central hypoventilation syndrome. Clinical case
Valentina Ivanovna Guzeva, Russian Federation

P369  Clinical heterogeneity and its potential therapeutic implications in children with SCN2A-related disorders
Katrine M Johannesen, Denmark

P370  A family with epilepsy and intellectual disability due to an ARHGEF9 mutation
Karl Martin Klein, Germany

P371  Diagnostic targeted next generation sequencing in patients with epilepsy
Patrick Rump, Netherlands

P372  Diagnostic epilepsy gene panel testing – first results from the Czech Republic
Katalin Štěrbová, Czech Republic

P373  830 monogenic diseases with epilepsy or seizures – a contemporary gamut of epilepsy genetics
Birute Tumiene, Lithuania
**MONDAY 12TH SEPTEMBER**

**NEUROIMAGING 1**

13:00 – 14:30

**P401** Bilateral thalamic volume loss in patients with pharmaco-resistant temporal lobe epilepsy with and without hippocampal sclerosis
Stanislav A Groppa, Moldova, Republic of

**P402** Directed functional connectivity during interictal spikes: a simultaneous intracranial and high-density scalp EEG study
Ana Coito, Switzerland

**P403** Diffusion tensor imaging and MRI tractography of the brain in patient with epilepsy and depression
Tatiana Kapustina, Russian Federation

**P404** Altered basal ganglia-cortical connections in frontal lobe epilepsy using resting-state fMRI functional connectivity analysis
Tiejun Liu, China

**P405** Beamforming improves ripple visibility in scalp EEG
Arjen Mol, Netherlands

**P406** Brivaracetam enters the human brain faster than Levetiracetam
Jonas Hannestad, Belgium

**P407** Distinctive patterns of seizure-induced white matter damage in right and left temporal lobe epilepsy
Irena Štěpán-Buksakowska, Czech Republic

**P408** Altered functional connectivity in temporal lobe epilepsy patients with verbal memory impairment
Naoki Tani, Japan

**P409** Contributions of regional properties on patient network connectomics
Peter Neal Taylor, United Kingdom

**P410** Decreased default mode network in drug-resistant generalized tonic-clonic seizures
Zhongyuan Wang, China

**MONDAY 12TH SEPTEMBER**

**NEUROPSYCHOLOGY AND PSYCHIATRY IN EPILEPSY 1**

13:00 – 14:30

**P442** Epilepsy and depression: Recognizing the double burden in Albania
Serla Grabova, Albania

**P443** Long term follow-up of neuropsychological outcome in patients with temporal lobe epilepsy
Candan Gurses, Turkey

**P445** Complexity of ictal-onset ECoG patterns in patients with type II cortical dysplasia
Antonina Kozlova, Russian Federation

**P446** Comparative descriptive of psychic and emotional state of parents bringing up children with chronic neurologic pathology
Alisa Kudlatch, Belarus

**P447** Generalized epileptiform activity in sleep disrupts cognitive functions in children with intractable extratemporal epilepsy
Vilém Novák, Czech Republic

**P450** Developmental delay in Verbal working memory (WM) at the start of primary school in children with epilepsy compared to controls matched for verbal short term memory (STM)
Loretta van Iterson, Netherlands

**P451** Neuropsychological outcome after temporobasal versus transsylvian approach for selective amygdalohippocampectomy in patients with temporal lobe epilepsy – a randomized prospective clinical trial
Viola Vogt, Germany

**P452** Emotion recognition in patients with mesial temporal lobe epilepsy
Oliwia Zaborowska, Poland

**P444** Cognitive problems in children and adolescents with epilepsy: validity of a standardized proxy report measure (KOPKIJ)
Christoph Helmstaedter, Germany

**P448** Are the neuropsychological profiles of temporal lobe epilepsy patients with neuronal auto-antibodies different?
Mine Sezgin, Turkey

**P449** A 7 year neuropsychological follow-up of a well functioning girl with Aicardi syndrome
Mia Tuft, Norway
MONDAY 12TH SEPTEMBER

13:00 – 14:30  OTHERS 1

P473  Clinical response to oral cannabis extracts in severe refractory epilepsy: preliminary experience in chilean patients
Gisela Kuester, Chile

P474  Perception and used of alternative treatment among patients with epilepsy
Suinee Lertsinudom, Thailand

P475  Beta lactams antibiotic ceftriaxone modulates seizures, oxidative stress and connexin 43 (Cx43) expression in hippocampus of pentylenetetrazole kindled rats
Khaled Sadek, Egypt

P476  Stress and seizures: development and piloting of a self-help stress management intervention for patients with seizures
Barbora Novakova, United Kingdom

P477  Quantitative biomarker of VNS therapy using EEG data
Maryam Ravan, USA

P478  Role of oxidative stress, neuroprotective heat shock protein 70 and connexin 43 in pentylenetetrazole-induced seizures in rats: possible protective effect of ferulic acid
Khaled Sadek, Egypt

P479  The efficacy of an 8 day comprehensive care program for inpatients with epilepsy
Frank Seyer, Germany

P480  Low glycemic index diet for the treatment of refractory epilepsy in children and young adults: a systematic review of efficacy
Leeha Singh, India

P481  Experience of using intravenous immunoglobulin for treatment of resistant forms of epilepsy in children
Tetiana Stetsenko, Ukraine

13:00 – 14:30  OTHERS 2

P482  Zinc treatment in epilepsy due to PIGA mutations
Marie Therese Abi Warde, France

P483  Investigation of the expression of calcium binding proteins in somatosensory cortex of WAG/Rij rats
Sertan Arkan, Turkey

P484  Evaluation of synaptic protein alterations during the acute, sub-acute, and chronic inflammatory response following status epilepticus (SE)
Una Avdic, Sweden

P485  In vivo longitudinal changes in interictal metabolism and cannabinoid type 1 receptor expression during temporal lobe epileptogenesis
Evy Cleeren, Belgium

P486  Expression of miR22 in mesial temporal lobe epilepsy patients: a preliminary study
Bárbara Leal, Portugal

P487  2-deoxy-D-glucose-mediated deceleration of kindling-induced epileptogenesis is reflected by 18-F-FDG brain kinetics
Ina Leiter, Germany

P488  Activation of transforming growth factor beta (TGFβ) signalling in mesial temporal lobe epilepsy (MTLE) patients
Debasmita Paul, India

P489  The impact of music on the bioelectrical activity of the brain in children with idiopathic epilepsy
Domantė Sakalauskaitė, Lithuania

P490  The Mozart effect comparing in children and adults with intractable epilepsy
Sheida Shaafi, Iran, Islamic Republic of

P491  Expression of MRP/ P-glycoprotein in pharmacoresistant temporal lobe epilepsy in PTZ-kindled mice
Mehwish Tanveer, Pakistan
MONDAY 12th SEPTEMBER

13:00 – 14:30  OTHERS 3

P492  Anticonvulsant and neuroprotective effects of argan oil on pilocarpine model induced status epilepticus in Wistar rats
Youssef Bhabiti, Morocco

P493  Role of the RNA-binding proteins Pumilio 2 and Staufen 2 in epileptogenesis – impacts on neurogenesis and long-term memory
Antonia Demleitner, Germany

P494  The SeLECT score: a novel tool to predict seizures after ischemic stroke
Marian Galovic, United Kingdom

P495  The study of citicoline (cytidine 5′-diphosphocholine) effect on seizure-induced neuronal death
Sung-Hee Hwang, Korea, Republic of

P496  Presurgical diagnosis and differentiated surgical treatment of drug-resistant focal and multifocal temporal lobe epilepsy basing on epileptogenesis conception
Svetlana Kravtsova, Russian Federation

P497  Diagnostic challenges in non-epileptic psychogenic seizures
Gulnighal Kutlu, Turkey

P498  Novel biallelic missense mutations in CTC1 gene identified in a Chinese family with cerebroretinal microangiopathy with calcification and cysts (CRMCC)
Hua Lin, China

P499  Whole exome sequencing reveals novel NOV and DCAF13 mutations in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy
Hua Lin, China

P500  Ischemia and inflammation are involved in the onset of epilepsy in Sturge-Weber syndrome
Madoka Nakajima, Japan

P501  Low levels of secure attachment styles in patients with psychogenic non-epileptic seizures
Antonia Villagran, Norway

P543  Effect on serum vitamin D levels and bone mineral density in children aged 3 to 14 years with newly diagnosed epilepsy on 6 months of valproate monotherapy – a longitudinal study
Sheffali Gulati, India

P544  A retrospective study of Lacosamide efficacy and tolerability as early and late add-on treatment in adult patients with focal epilepsy
Andrew Lawley, United Kingdom

P545  A randomized, open-label, parallel group, multi-center comparative trial of levetiracetam and topiramate as adjunctive treatment in refractory focal epilepsy
Byung-In Lee, Korea, Republic of

P546  Alteration in grey matter volumes in children of mothers with epilepsy
Ruma Madhu Sreedharan, India

P547  A validated high performance liquid chromatographic method for lamotrigine analysis in plasma samples
Janet Mifsud, Malta

P548  Some words about the effectiveness of perampanel as adjunctive therapy for pharmacoresistant epilepsy in children
Gulisa Musina, Russian Federation

P549  Adverse drug reaction of antiepileptic drugs in epilepsy clinic, Tertiary Hospital, Thailand
Thanida Nuntasaen, Khonkaen, Thailand

P550  Add-on antiepileptic drug treatment in patients with seizures after epilepsy surgery
Michal Ryzi, Czech Republic
### MONDAY 12TH SEPTEMBER

#### PHARMACOLOGY/AEDS 2

| P566 | Antiictogenic and antiepileptogenic properties of perampanel in mature and immature rats  
Stéphane Auvin, France |
|------|-------------------------------------------------------------------------------------------------------------------|
| P567 | Analysis of antiepileptic drug selection based on the known mechanism of action in difficult-to-treat partial epilepsy  
Gábor Barcs, Hungary |
| P568 | Alzheimer’s disease, epilepsy and eslicarbazepine  
Pedro Emilio Bermejo, Spain |
| P569 | Antiepileptic drug-induced skin reactions in Polish patients with epilepsy  
Magdalena Bosak, Poland |
| P570 | Availability of antiepileptic drugs in primary care hospitals of northeastern, Thailand  
Nanthaphan Chainirun, Thailand |
| P571 | Clinical use of PER in real-life clinical setting: a retrospective study in patients with “super-refractory” epilepsies  
Jinane Fattouch, Italy |
| P572 | Bone metabolism serum markers in adult patients with epilepsy and effect of Vitamin D administration on the control of seizures  
Mario Tombini, Italy |
| P573 | Clinical effects and MRI morphometry changes after using antiepileptic drugs in temporal lobe epilepsy in Uzbekistan  
Azamatjon Umarov, Uzbekistan |

#### PHARMACOLOGY/AEDS 3

| P574 | Drug and substance abuse in refractory epilepsy  
Raafat Abdeldayem, Egypt |
|------|-------------------------------------------------------------------------------------------------|
| P575 | Effectiveness and tolerability of Perampanel in children and adolescents with refractory epilepsies – an Italian multicenter study  
Paola De Liso, Italy |
| P576 | Effectiveness of perampanel as adjunctive therapy in patients with refractory focal seizures with GCI assessment  
Giovanni De Maria, Italy |
| P577 | Effect of valproic acid on the placental barrier in the pregnant mouse: optical imaging and transporter expression studies  
Sara Eyal, Israel |
| P578 | Effectiveness of eslicarbazepine acetate as adjunctive therapy for partial epilepsy in clinical practice: design of a European pooled analysis of real-world data  
Rob McMurray, United Kingdom |
| P579 | Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: a prospective multicenter study  
Rodrigo Rocamora, Spain |
| P580 | Effect of Perampanel over the quality of sleep and daytime somnolence in focal epilepsy  
Javier Salas-Puig, Spain |
| P581 | Effectiveness and tolerability of lacosamide in Thai children & adolescents with intractable epilepsy  
Chaiyos Khongkhatithum, Thailand |
MONDAY 12TH SEPTEMBER

13:00 – 14:30 PROGNOSIS/EPIDEMIOLOGY 1

P630 Epidemiology of focal and generalized onset seizures in Algeria
Walid Abdellaoui, Algeria

P631 A picture of clinical research in epilepsy
Maria Grazia Celani, Italy

P632 Clinical and etiological profiles of adult patients with symptomatic epilepsy in Bishkek
Asel Jusupova, Kyrgyzstan

P633 Descriptive analysis of status epilepticus among patients admitted in the medical intensive care unit and neurological intensive care unit from January 2010 to December 2014
Ronald Ramos, Philippines

P634 Comparison of patients with status epilepticus or epileptic seizure admitted to the emergency room
Sophie Reinecke, Germany

P635 Comorbidity of epilepsy
Irina Stefanova, Bulgaria

P636 Epidemiology of seizures in children with neuroinfections
Anna Surovtseva, Russian Federation

P637 A comparison from Mexico and Canada of waiting times for assessment and epilepsy surgery
Jose F. Tellez-Zenteno, Canada

13:00 – 14:30 STATUS EPILEPTICUS 1

P655 Emergent vagal nerve stimulator implant during paediatric refractory status epilepticus: report of three cases
Andrea Landi, Italy

P656 Diagnostic accuracy of Salzburg-criteria for nonconvulsive status epilepticus
Markus Leitinger, Austria

P657 Correlation of inflammatory cytokines, synaptic proteins and growth factors in the immunopathogenesis of temporal lobe epilepsy
Vinod Kumar Mehta, India

P658 Electroclinical features and outcomes in new onset refractory status epilepticus with Claustrum damage
Stefano Meletti, Italy

P659 Endogenous neurosteroids levels are decreased in CSF during status epilepticus
Giulia Monti, Italy

P660 Did new definition of status epilepticus have impact on its incidence in older patients with acute stroke?
Petar Nikic, Serbia

P661 Efficacy and tolerability of intravenous lacosamide in treatment of status epilepticus in elderly epileptic patients
Nicola Paciello, Italy

P662 Comparison of the effectiveness of four antiepileptic drugs in treatment of status epilepticus according to four different efficacy criteria
Johannes Rösche, Germany

P663 Cryptogenic focal epilepsy presenting as new onset refractory status epilepticus (NORSE): implication of autoimmunity?
Martha Spilioti, Greece
MONDAY 12TH SEPTEMBER

13:00 – 14:30 SURGICAL TREATMENT AND NEUROMODULATION 1

P683 Occurrence of abnormal rhythmic transients and the response to stimulation in a computational model of epileptiform activity
Gerold Baier, United Kingdom

P684 Prolonged seizure remission after electrode insertion in patients submitted to hippocampal deep brain stimulation (Hip-DBS) for refractory temporal lobe epilepsy
Arthur Cukiert, Brazil

P685 Post-operative contacts’ location in patients submitted to hippocampal deep brain stimulation (Hip-DBS)
Cristine Cukiert, Brazil

P686 Efficacy of vagal nerve stimulation in a cohort of 32 drug-resistant epileptic paediatric patients
Daniele Grioni, Italy

P687 Cortical autonomic and respiratory control structures in patients with epilepsy
Nuria Lacuey Lecumberri, USA

P688 Altered cortical excitability in drug-naïve epilepsy patients
Jung Hwa Lee, Korea, Republic of

P689 High spectral changes induced by SPES- a comparison between physiologic and pathologic network interaction in SEEG
Mihai Dragos Maliia, Romania

P690 Electrical continous neuromodulation in the internal globus pallidus for treatment of drug-resistant myoclonus (and refractory epilepsy) in patients suffering from the Unverricht-Lundborg disease
Blanca Mercedes Alvarez, France

P691 Effects of vagal nerve stimulation on people with epilepsy and cognitive disabilities
Eva Pipan, Slovenia

TUESDAY 13TH SEPTEMBER

13:00 – 14:30 BASIC SCIENCE 3

P129 Nucleus dentatus role in the suppression of focal cortical epileptic activity
Valeria Chubach, Ukraine

P130 Endogenous kynurenic acid, a tryptophan metabolite, synthesis is decreased in resected brain specimens obtained from patients with mesial temporal lobe epilepsy
Soumil Dey, India

P131 Oxidative stress and mitochondrial dysfunction in immature brain during epileptogenesis
Jaroslava Folbegrová, Czech Republic

P132 Neocortical gamma-oscillations before stimulus presentation predict successful memory encoding in humans – an intracranial EEG-study
Stephanie Gollwitzer, Germany

P133 Methionine nutritional overload facilitates epilepogenesis: possible role of modulation of rat brain Na+/K+-ATPase and E-NTPDase activity
Dragan Hrncic, Serbia

P134 Effective connectivity changes reveal neuronal population activity during seizures in humans
Radek Janca, Czech Republic

P135 Focal 4-aminopyridine-induced seizure-like events initiated by inhibitory network activity induce [K+]0 increase, but are not dependent on KCC2 channels
Laura Librizzi, Italy

P136 Neuronal firing analysis of epileptic interictal activity in humans
Andreas Schulze-Bonhage, Germany

P137 Gene expression analysis of drug transporters & biotransformation enzyme in patients with mesial temporal lobe epilepsy & focal cortical dysplasia: a comparative study
Devina Sharma, India

P138 Epilepsy may cause increased pain sensitivity: preliminary data from absence epileptic WAG/Rij rats nociceptive threshold
Sibel K Velioglu, Turkey

P139 Mechanisms underlying different onset patterns of focal seizures
Yuijiang Wang, United Kingdom
**TUESDAY 13TH SEPTEMBER**

13:00 – 14:30  **BASIC SCIENCE 4**

P140  **Sirt3 mediates antioxidant defense via regulating MnSOD activity in mouse hippocampus after pilocarpine-induced status epilepticus**  
In Ja Cho, Korea, Republic of

P141  **The rhythm specificity of DMN during temporal lobe epilepsy seizure**  
Yan Cui, China

P142  **Single microvascular pericyte tracking during epileptiform activity in vitro**  
Frederic de Bock, France

P143  **Spontaneously hypertensive rats with cerebral small vessel disease are prone to temporal lobe epilepsy**  
Giovambattista De Sarro, Italy

P144  **The role of oxidative stress in neurodegeneration in the immature brain following status epilepticus**  
Lubica Demeterova, Czech Republic

P145  **The role of adenosine in hippocampal excitability after status epilepticus in immature and adult rats**  
Petr Fabera, Czech Republic

P146  **A low-noise amplifier improves automated fast ripple (FR) detection in intraoperative ECoG**  
Tommaso Fedele, Switzerland

P147  **Asymmetry in temporal lobe cortex organisation**  
Adam Kalina, Czech Republic

P148  **The implication of Cav1 and Ca2+-dependent cation channels in PDS formation**  
Helmut Kubista, Austria

P149  **Allopregnanolone is reduced in patients with PCDH19-related epilepsy**  
Marina Trivisano, Italy

P150  **The correlation study between electrophysiological DMN and cognitive impairment based on experimental TLE rats**  
Yang Xia, China

---

**TUESDAY 13TH SEPTEMBER**

13:00 – 14:30  **CLINICAL EPILEPSY 3**

P186  **Pregnancy and perinatal outcome in Chinese epileptic women: prospective continuous hospital based registration study**  
Lei Chen, China

P187  **Anti-mullerian hormone is higher in women with epilepsy who report seizure-freedom compared to those who report ongoing seizures**  
Cynthia Harden, USA

P188  **Pregnancy outcome in women with epilepsy beyond child age of one year**  
Gordana Kiteva-Trenchevska, Macedonia, the Former Yugoslav Republic of

P189  **Gender features of drug resistance in female epilepsy**  
Anastasia Chugunova, Russian Federation

P190  **Effect of UGT1A4 and UGT2B7 polymorphism on lamotrigine metabolism during pregnancy**  
Vaiva Petrenaitė, Denmark

P191  **The use of lacosamide in elderly patients**  
Sirpa Rainesalo, Finland

P192  **Effects of valproic acid on the expression of folate transporters in the human placenta**  
Nino Tetro, Israel

P193  **Plasma and breast milk levels of lacosamide before, during and post pregnancy**  
Jana Zarubova, Czech Republic
**TUESDAY 13TH SEPTEMBER**

13:00 – 14:30  **CLINICAL EPILEPSY 4**

P194  The rate of congenital malformations in epileptic pregnant patients: a prospective study
Hacer Bozdemir, Turkey

P195  Pregnancy-related knowledge of women with epilepsy – an internet based survey in German speaking countries
Carolin Dierking, Germany

P196  Development and validation of modified INCLEN diagnostic instrument for epilepsy in children aged up to 18 years
Sheffali Gulati, India

P197  Quality of life in children with epilepsy
Valentina Ivanovna Guzeva, Russian Federation

P198  Characteristics and health care of adult tuberous sclerosis complex (TSC) patients in German epilepsy centers
Hajo Hamer, Germany

P199  Seizure control and antiepileptic drug use by pregnant women with epilepsy enrolled in China
Nanya Hao, China

P200  Women and epilepsy: a review of practices in the public and private setting in Jamaica, 2012 – 2015
Uma Menon, USA

P201  Yes you can: a video for women with epilepsy planning a family
Catie Picton, United Kingdom

P202  Service availability of phenytoin products for treatment of epilepsy in government hospitals in Thailand
Thanarat Suansanae, Thailand

P203  Survey of the awareness and clinical practice of medical association members regarding comprehensive management of epilepsy in the San-in region of Japan
Shin-Ichi Yoshioka, Japan

---

14:30 – 16:00  **CLINICAL NEUROPHYSIOLOGY 3**

P242  How useful is repeat continuous EEG monitoring in the intensive care unit?
Jeffrey M. Chung, USA

P243  Ictal pattern on scalp EEG indicates resection area in mesial temporal lobe epilepsy
Izumi Itabashi, Japan

P244  Paroxismal brain: epilepsy and panic attack
Vladimir Karlov, Russian Federation

P245  Impact of video-ambulatory electroencephalography on the medical management of epilepsy
Francesco Manfredonia, United Kingdom

P246  Perampanel in add-on: effect on EEG background activity and efficacy on seizure control in patients with brain tumour-related epilepsy. Preliminary data
Marta Maschio, Italy

P247  Frequency, pattern and determinants of electrocardiographic markers of sudden cardiac arrest in black African patients with epilepsy in Enugu, South East Nigeria
Orakwue Molokwu, Nigeria

P248  Photosensitivity is an early marker of infantile neuronal ceroidlipofuscinosi (NCL-2)
Nicola Pietrafusa, Italy

P249  MEG connectivity for the lateralization of language – a proof of concept
Stefan Rampp, Germany

P250  Olfactory dysfunction in patients with mesial temporal lobe epilepsy: what is the difference of the problem?
Bedia Samanci, Turkey

P251  Laterlization of receptive language function in epilepsy patients: a high resolution scalp-derived event-related potential (ERP) study
Karin Trimmel, Austria
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  EPILEPSY IN CHILDHOOD 5

P322  Etiology in childhood-onset temporal lobe epilepsy  
Walid Abdellaoui, Algeria

P323  Features epilepsy in patients with cerebral palsy  
Ikbol Abdusakirova, Uzbekistan

P324  Features of epilepsy in children with complicated perinatal history  
Elena Morozova, Russian Federation

P325  Febrile infection-related epilepsy syndrome (FIRES) and super-refractory status epilepticus in children  
Sofia Quintas, Portugal

P326  Febrile seizures clinical features in patients with afterwards epilepsy  
Leanid Shalkevich, Belarus

P327  Glucose transporter deficiency type 1 (GLUT1-DS) due to gene SLC2A1 mutations – how often epileptic patients display movement disorders. Experience from one Polish medical centre  
Elzbieta Szczepanik, Poland

P328  Hemispheric lateralization in benign focal epilepsy in childhood with centrotemporal spikes (BECTS) in Uzbekistan  
Ruzieva Dilnoza, Uzbekistan

P329  Frequency of tuberous sclerosis complex diagnosis in pediatric patients the last 15 years in the island of Crete  
Pelagia Vorgia, Greece

P330  Frequency-dependent changes of neural networks from pre-ictal to ictal stages in childhood absence epilepsy  
Xiaoshan Wang, China

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  EPILEPSY IN CHILDHOOD 6

P331  Incidence of febrile seizures and risk of subsequent epilepsy in children with febrile seizures  
Kari Modalsli Aaberg, Norway

P332  Ketogenic versus modified Atkins diet for epilepsy: a single centre experience from Singapore  
Jeannie Chiam, Singapore

P333  Idiopathic epilepsies child: study of a retrospective cohort of 186 children followed during 3 years at fann teaching hospital (Dakar – Senegal)  
Maouly Fall, Senegal

P334  Post-stroke epilepsy in children: a retrospective cross-sectional study in Dakar  
Daniel Gams Massi, Senegal

P335  Inertial sensor based epileptic seizure detector  
Martin Kudr, Czech Republic

P336  Mutations in the CACNA1A gene as cause of epilepsy and of different (paroxysmal) movement disorders in 20 patients: common therapeutic approaches?  
Svetlana Moiseeva, Germany

P337  Hot water epilepsy clinical profile and treatment. analysis of 13 cases from Kayseri  
Hüseyin Per, Turkey

P338  Perampanel in therapy of drug-resistant epilepsies in children  
Svetlana Sivkova, Russian Federation
**TUESDAY 13TH SEPTEMBER**

**13:00 – 14:30  EPILEPSY IN CHILDHOOD 7**

**P339** The neurological outcome of high-risk infants with neonatal seizures  
Natasa M. Cerovac, Serbia

**P340** The relationship of clinical factors to antiepileptic drug adherence  
So-Hee Eun, Korea, Republic of

**P341** Roles of globus pallidus externa in controlling absence seizures  
Daqing Guo, China

**P342** The correlation between febrile seizure and unprovoked seizure followed by febrile seizure  
Seunghyo Kim, Korea, Republic of

**P343** The burden of frequent seizures on patients, parents and society in a European study of non-institutionalized children with epilepsy  
Lieven Legae, Belgium

**P344** Treatment of pediatric intractable epilepsy with vaporized cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC)- preliminary findings of the Israeli pediatric medical cannabis (MC) cohort  
Ilan Linder, Israel

**P345** Role of lead in provoking seizure in children: a case control study in Tehran, Iran  
Samileh Noorbakhsh, Iran, Islamic Republic of

**P346** The experience of using Zonegran to treat resistant epilepsy in children of early preschool age  
Nataliya Perunova, Russian Federation

**P347** Seizure duration with and without rescue medication in a European study of children who experience prolonged acute convulsive seizures  
Federico Vigevano, Italy

**TUESDAY 13TH SEPTEMBER**

**13:00 – 14:30  EPILEPSY IN CHILDHOOD 8**

**P348** Schooling of children with epilepsy  
Kegnide Christelle Cadnelle Affognon, Senegal

**P349** Typical absence epilepsy with onset before the age of four years-report of eleven patients  
Matilda Kovac Sizgoric, Croatia

**P350** 7p22.3 microdeletion and 6q26 microduplication found in Bulgarian patients with generalized epilepsy, autistic features and intellectual disability  
Valentina Peycheva, Bulgaria

**P351** Learning problems in children with early-onset epilepsy  
Kati Rantanen, Finland

**P352** Is there a relationship between constipation and an increase in seizures in people with learning disabilities and refractory epilepsy within a care setting?  
Sally-Ann Remnant, United Kingdom

**P353** Why medications don’t work: considerations for pseudo-refractory epilepsy in children  
Furkat Samadov, Uzbekistan

**P354** Relationship of simple reaction time and spike frequency in benign childhood epilepsy with centrotemporal spikes  
Ruta Samaitiene, Lithuania

**P355** Clinical symptoms, EEG, MRI and psychological analysis of 16 patients with CSWS or ESES  
Anna Winczewska-Wiktor, Poland

**P356** Decision making process and somatic markers in patients with occipital lobe epilepsy  
Naz Yeti, Turkey
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  GENETICS 2

P374  Gender-related pharmacogenomics of transport- and target-proteins in drug resistant epilepsy patients
Dimitrios Chatzistefanidis, Greece

P375  Expanding the phenotype of TSC1 deletion – it’s not always what you expect
Tal Gilboa, Israel

P376  Duplications of the SLC9A6 gene cause syndromic intellectual disability with status epilepticus during slow-wave sleep – a new type of gene mutations involving the NHE6 dysfunction in ESES
Dorota Hoffman-Zacharska Dorota, Poland

P377  Epilepsy in patients with Down syndrome
Alexey Kholin, Russian Federation

P378  Experiences of receiving a genetic diagnosis and the impact on everyday life
Ditte B. Kjelgaard, Denmark

P379  Expanding the clinical spectrum associated with SLC6A1 mutations
Rikke Møller, Denmark

P380  Exome sequencing of families with autosomal dominant lateral temporal epilepsy (ADLTE) reveals a GRIN2A mutation in one family
Carlo Nobile, Italy

P381  Exome-based copy number variation analysis in patients with epileptic encephalopathies
Ramakrishnan Rajagopalan, USA

P382  Diagnostic whole exome sequencing in 100 individuals with both epilepsy and intellectual disability
Francesca Snoeijen-Schouwenaars, Netherlands

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  GENETICS 3

P383  Linkage analysis in medium sized families as a tool to prioritize variants from exome sequencing
Zaid Afawi, Israel

P384  NTRK2 gene variants display association with temporal lobe epilepsy
Marino Muxfeldt Bianchin, Brazil

P385  Mutations in the PCDH19 gene in Polish patients with Dravet – like syndrome phenotype
Paulina Górka-Skoczylas, Poland

P386  Lack of pathogenic variants in SCN1A gene in familial febrile seizures with mesial temporal lobe epilepsy
Ioanna Koussiappa, Cyprus

P387  Novel phenotypic- and functional aspects of heterozygous de novo mutations in GRIN2B
Johannes Lemke, Germany

P388  Loss-of-function of the retinoid-related nuclear receptor (RORB) gene and epilepsy
Gaetan Lesca, France

P389  Next generation sequencing in rare childhood epilepsy of suspected genetic etiology
Francesca Ragona, Italy

P390  Gene IL-1B polymorphism and recurrent febrile seizures at children
Anna Diuzhakova, Russian Federation
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  NEUROIMAGING 2

P411  MRI abnormalities and EEG patterns of symptomatic epilepsy in children with cerebral palsy
       Khabibulla Aminov, Uzbekistan

P412  Non-invasive data-driven connectivity analysis correspond with areas of initial seizure propagation found by prior modalities from the hypothalamus
       Varina Boerwinkle-Wolf, USA

P413  Mapping language in temporal lobe epilepsy – results of a functional connectivity and network-based analysis
       Silvia Bonelli, Austria

P414  Objective background of the refractory epilepsy development founded on structural-metabolic alterations of the brain
       Volha Kistsen, Belarus

P415  Morphological changes of cerebellum in epilepsy: Hypertrophy of selected vermis segments in patients with temporal lobe epilepsy
       Václav Marcián, Czech Republic

P416  MRI volumetry of temporal lobes and its substructures in pharmaoresistant temporal lobe epilepsy patients
       Lukas Martinkovic, Czech Republic

P417  Nodular heterotopia: integration of multimodal neuroimaging and neurophysiological methods
       Irene Pappalardo, Italy

P418  Does automated morphometric screening support MRI diagnostics in temporal lobe epilepsy patients?
       Christian Rummel, Switzerland

P419  Investigation of global network synchrony in resting-state functional magnetic resonance imaging of patients with mesial temporal lobe epilepsy: a pilot study
       Siti Nurbaya Yaakub, United Kingdom

P420  Paediatric clinical fMRI for epilepsy surgery
       Arshad Zaman, United Kingdom

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  NEUROPSYCHOLOGY AND PSYCHIATRY IN EPILEPSY 2

P453  Seizure counting of clinical drug trial participants
       Barbara Blachut, Germany

P454  Epilepsy in elderly people and affective disorders
       Andrey K. Druzhinin, Russian Federation

P455  Autoimmune (limbic and extralimbic) encephalitis – our recent experience with the new etiology of epilepsy
       Veronika Jakubčiaková, Czech Republic

P456  Preliminary first Czech validation of EpiTrack®
       Alena Javůrková, Czech Republic

P457  Clinical course of personality disorder associated with epilepsy
       Seo-Young Lee, Korea, Republic of

P458  Risk for verbal memory deficits caused by depth hippocampal electrodes: an explorative study
       Hanna Ljung, Sweden

P459  Ethical, clinical, and social aspects of treatment of epilepsy in patients with comorbid depression
       Ekaterina P. Mikhalkovska-Karlova, Russian Federation

P460  Social cognition and prefrontal functions in patients with epilepsy treated with eslicarbazepine
       Angela Sanabria, Spain

P461  Social cognition and emotion perception in patients with juvenile myoclonic epilepsy
       Elisabeth Schmid, Austria

P462  A systematic review of neuropsychiatric comorbidities in patients with both epilepsy and intellectual disability
       J.S. van Ool, Netherlands
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  OTHERS 4

P502  Sleep disordered breathing in patients with epilepsy – a polysomnographic study
Katarina Klobučníková, Slovakia

P503  The role of anxiety in the onset of epileptic seizures in Greek patients
Anna Maria Mouzak, Greece

P504  Stress and seizures: exploring the patterns of implicit attentional biases in patients with epilepsy and dissociative seizures
Markus Reuber, United Kingdom

P505  Management of patients with psychogenic nonepileptic seizures in South Africa: a survey of healthcare professionals
Chrisma Pretorius, South Africa

P506  A collaborative framework for the development and evaluation of an epilepsy first aid training intervention
Darlene Snape, United Kingdom

P507  Relapsing seizures after resective epilepsy surgery – are they always epileptic?
Anke Staack, Germany

P508  Stroke like migraine after radiation therapy syndrome induced by implantation of intracerebral deep electrodes
Alexander Timofeev, France

P509  The Minnesota multiphasic personality inventory-2 profile in patients with psychogenic non-epileptic seizures
Zdenek Vojtech, Czech Republic

P510  A critical evaluation of the role and effectiveness of the UK epilepsy specialist nurse
Elizabeth Wright, United Kingdom

P511  Stereotypy of psychogenic non epileptic seizures
Moshe Herskovitz, Israel

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  OTHERS 5

P512  Cross-cultural adaptation and validation of the Portuguese version of the quality of life questionnaire in epilepsy (QOLIE-89)
Anabela Almeida, Portugal

P513  Diagnostic accuracy of audio based seizure detection in patients with severe epilepsy and a mental impairment
Johan Arends, Netherlands

P514  Establishment of epilepsy group education – a local experience 2 years on
Claire Behan, Ireland

P515  Automated assessment of electrode reduction on detection of EEG patterns in intensive care patients
Johannes Herta, Austria

P516  Demographic and clinical findings of epilepsy patients who underwent follow-up at the newly established clinic of Mugla University Faculty of Medicine
Gulnihal Kutlu, Turkey

P517  Epilepsy patient’s referral pattern to the epilepsy center in Korea
Jun Hong Lee, Korea, Republic of

P518  Cochrane review of psychological treatments for people with epilepsy
Rosa Michaelis, Germany

P519  Carer perception of focal seizures in canine epilepsy
Rowena M.A. Packer, United Kingdom

P520  Frequency and the severity of complications during the Wada test
Andrzej Rysz, Poland

P521  An unusual feature of adult-onset fulminant SSPE
Sanja Vodopic, Montenegro

P522  Epilepsy and seizures in patients with low-grade gliomas: Is the current adult service delivering best practice?
Freya Waite-Taylor, United Kingdom

P523  Evaluation of left ventricular diastolic function by tissue Doppler imaging in patients with newly diagnosed and untreated focal epilepsy
Deniz Yerdelen, Turkey
TUESDAY 13TH SEPTEMBER

13:00 – 14:30 PHARMACOLOGY/AEDS 4

P582 Effectiveness of perampanel in refractory epilepsies: data from an apulian (Italy) open label study
Giovanni Boero, Italy

P583 Effectiveness of perampanel as adjunctive therapy in patients with refractory seizures
Paolo Bonanni, Italy

P584 Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures
Giuseppe Borzì, Italy

P585 Effectiveness of rufinamide in adults with Lennox-Gastaut syndrome – a monocentric retrospective audit
Anna-Lena Friedo, Germany

P586 Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in patients with focal seizures
Laura Mumoli, Italy

P587 Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsy: a questionnaire-based study
Andrea Romigi, Italy

P589 Efficacy and tolerability of monotherapy with lacosamide versus controlled-release carbamazepine in elderly patients with newly diagnosed epilepsy: a subgroup analysis of a prospective randomized double-blind trial
Felix Rosenow, Germany

P588 Efficacy of lacosamide monotherapy in patients with newly diagnosed epilepsy stratified by baseline disease severity: sub-analysis of data from a prospective non-inferiority trial versus controlled-release carbamazepine
Manuel Toledo, Spain

TUESDAY 13TH SEPTEMBER

13:00 – 14:30 PHARMACOLOGY/AEDS 5

P590 European non-interventional registry study of antiepileptic drug use in patients with Lennox-Gastaut syndrome
Stéphane Auvin, France

P591 Evaluation of preventive and neuroprotective effects of chronic daily topiramate, lacosamide and levetiracetam administration on pentylenetetrazol-induced status epilepticus in newborn rats
Özgür Duman, Turkey

P592 Focal inter-ictal epileptiform activity in the EEG supressed by levetiracetam, a diagnostic problem in pre-treated patients
Koenig Kristina, Switzerland

P593 Fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients
An-Sofie Schoonjans, Belgium

P594 Efficacy of perampanel by baseline seizure frequency in patients with partial seizures
Michael Sperling, USA

P595 Experience in the treatment of nocturnal seizures with lacosamide
Mónica Villas, Spain

P596 Innovative drug perampanel in the treatment of focal epilepsies
Irina Zhidkova, Russian Federation

P597 Eslicarbazepine vs brivaracetam for adults with refractory partial seizures: a meta-analysis
Xiaoyi Zou, China
TUESDAY 13th SEPTEMBER

13:00 – 14:30  PHARMACOLOGY/AEDS 6

P598  Mental retardation, refractory epilepsy and treatment with eslicarbazepine
Pedro Emilio Bermejo, Spain

P599  Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: a long-term study on 136 patients
Stefan Boettcher, Germany

P600  Long term effectiveness of perampanel: the Leeds experience
Jo Geldard, United Kingdom

P601  Long-term impact of antiepileptic drug treatment on cognitive development
Dominique Ijff, Netherlands

P602  Long-term efficacy, tolerability and retention rate of add-on lacosamide treatment in 105 children and adolescents with refractory epilepsy: a single centre retrospective observational study from Italy
Lucrezia Ilvento, Italy

P603  Management of adverse events due to perampanel and levetiracetam interactions
Galina Odintsova, Russian Federation

P604  No association between skin reactions from lamotrigine and UGT 1a4 variants *2 and *3
Maryam Shirzadi, Norway

P605  Optimising the control of the triggered epileptic attacks
Radwan Zaidan, Saudi Arabia

---

TUESDAY 13th SEPTEMBER

13:00 – 14:30  PHARMACOLOGY/AEDS 7

P606  Perampanel as adjunctive drug in children and young adults with refractory epilepsy
Giangennaro Coppola, Italy

P607  Pharmacovigilance of lamotrigine and valproate in Norway, 2004-2013
Maren Lima, Norway

P608  Own experience with perampanel, eslicarbazepine and zonisamide in the treatment of patients with epilepsy
Svetlana Nurmukhametova, Russian Federation

P609  Real world data of perampanel as adjunctive therapy in a german epilepsy center
Max Christian Pensel, Germany

P610  PROMETEO: a prospective observational study to assess the treatment effect after introduction of a different AED in patients with partial epilepsy fulfilling the 2010 ILAE criteria of drug-resistant epilepsy
Emilio Perucca, Italy

P611  Perampanel in children and adolescents with refractory epilepsy: PMK Hospital, Thailand experience
Piradee Suwanpakdee, Thailand

P612  Quality of life and psychiatric symptoms in patients undertaking perampanel treatment: preliminary results of a prospective study
Flavio Villani, Italy

P613  Perampanel in routine clinical practice
Pavel Vlasov, Russian Federation
TUESDAY 13\textsuperscript{TH} SEPTEMBER

13:00 – 14:30 PROGNOSIS/EPIDEMIOLOGY 2

P638 Experience with first episode of consciousness loss assessment in a regional center of Romania
Adina Cuciureanu, Romania

P639 Evaluation of clinical features of patients with occipital lobe epilepsy, retrospectively
Sakir Delil, Turkey

P640 Secular trends in the incidence of epilepsy in the province of Saskatchewan, Canada (2001-2010)
Lizbeth Hernandez Ronquillo, Canada

P641 First epileptic seizure: Incidence and management of paroxysmal episodes in Ljubljana Emergency Unit for Neurology
Viktoria Kostadinova, Slovenia

P642 Injuries and accidents in epilepsy: a prospective, population-based cohort study on incident cases
Benno Mahler, Sweden

P643 Epilepsy in Qatar: causes, treatment and outcome
Gayane Melikyan, Qatar

P644 Prevalence of hospitalized in patients with epilepsy: a national data report from Thailand
Sineenard Pranboon, Thailand

P645 Prevalence and etiology of epilepsy in a Norwegian county – a population based study
Marte Syvertsen, Norway

TUESDAY 13\textsuperscript{TH} SEPTEMBER

13:00 – 14:30 STATUS EPILEPTICUS 2

P664 Neurobrucellosis presenting with status epilepticus as an initial symptom
Ali Akyol, Turkey

P665 Etiology, clinical profile and immediate outcome of convulsive status epilepticus in children: resource poor country perspective
Adhi Arya, India

P666 Lateralized periodic discharges associated with status epilepticus in the first year after stroke
Nerses Bebek, Turkey

P667 Interleukin 17A is associated with the severity of epilepsy and BBB interruption in pilocarpine induced status epilepticus model
Jing Ding, China

P668 Predicting the outcome of status epilepticus: comparison of STESS and EMSE score in a prospective, monocentric, adult population
Giada Giovannini, Italy

P669 Prognosis of status epilepticus in elderly patients
Estevo Santamarina, Spain

P670 Prognosis of status epilepticus (SE) patients requiring intravenous anesthetic drugs (IVAD)
Estevo Santamarina, Spain

P671 Fatal cerebral edema with status epilepticus in children with Dravet syndrome
Ingrid Scheffer, Australia

P672 Intravenous levetiracetam as second line option for status epilepticus and seizure clusters
Aurelian Ungureanu, Romania
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  SURGICAL TREATMENT AND NEUROMODULATION 2

P692 Vagus nerve stimulation and corpus callosotomy in refractory epilepsy – experience from a tertiary center in Rio de Janeiro
Isabella D Andrea-Meira, Brazil

P693 A prospective long-term study of health-related quality of life and mood after epilepsy surgery or pre-surgical work-up
Anna Edelvik, Sweden

P694 The effectiveness of vagal nerve stimulation therapy in patients with refractory epilepsy and mental retardation – a 12-month follow up
Jedrzej Flicinski, Poland

P695 A novel functional MRI paradigm for the pre-operative assessment of auditory perception in a musician undergoing temporal lobe surgery
Matthew Hale, United Kingdom

P696 TMS combined with EEG in genetic generalized epilepsy: A phase II diagnostic accuracy study
Vasilios K. Kimiskidis, Greece

P697 Vagus nerve stimulation in epilepsy: a long-term analysis for outcome
Elisabeth Landré, France

P698 A clinical, neuroradiological, and neurophysiological study with surgical outcome on 45 patients with drug-resistant partial epilepsy related to periventricular nodular heterotopia
Laura Mirandola, Italy

P699 Vagus nerve stimulation in Lafora body disease
Zeljka Petelin Gadze, Croatia

P700 Vagus nerve stimulation devices can be completely removed or replaced safely
Baris Turak, France

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  SURGICAL TREATMENT AND NEUROMODULATION 3

P701 Epilepsy surgery outcome – our center final results
Michal Bajaček, Czech Republic

P702 Endoscopic robot-guided disconnection of hypothalamic hamartomas: results in 18 cases
Alessandro De Benedictis, Italy

P703 Epilepsy surgery in children: clinical and follow-up data of the first 100 operated cases at the Bambino Gesù Children Hospital, IRCCS, Rome, Italy
Luca De Palma, Italy

P704 Correlation of surgical outcome with ictal and interictal EEG patterns in temporal lobe epilepsy
Swapan Gupta, India

P705 Frontal lobe epilepsy surgery in children: epilepsy syndromes, neuropathologies and seizure outcomes
Henna Jonsson, Finland

P706 Anterior callosotomy in children with Lennox-Gastaut syndrome (clinical cases)
Mikhail Nikolaenko, Russian Federation

P707 Dose callosotomy improve seizure and developmental prognosis in children with epileptic spasms in infancy and early childhood? Analysis of the FACE study
Taisuke Otsuki, Japan

P708 Health-related quality of life and emotional wellbeing in parents of children with epilepsy before and after epilepsy surgery
Colin Reilly, United Kingdom

P709 A simple and accurate frameless stereotactic implantation technique for stereo EEG depth electrodes in refractory epilepsy evaluated by intraoperative MRI imaging
Karl Roessler, Germany
<table>
<thead>
<tr>
<th>Session Time</th>
<th>Session Title</th>
<th>Presentation Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>TUESDAY 13TH SEPTEMBER</td>
<td>SURGICAL TREATMENT AND NEUROMODULATION 4</td>
<td>Mesial temporal lobe epilepsy: long-term outcome of a tailored approach</td>
<td>Christian Dorfer</td>
<td>Austria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Long-term outcome and neuroradiological changes after multiple hippocampal transection</td>
<td>Kensuke Kawai</td>
<td>Japan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Morbidity related to surgery of mesial temporal lobe epilepsy associated with hippocampal sclerosis</td>
<td>Bertrand Mathon</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Parental reports of family life situation at long-term after hemispherotomy</td>
<td>Anneli Ozanne</td>
<td>Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Outcome analysis of the surgical treatment for refractory frontal lobe epilepsy</td>
<td>Ana Paula Pinheiro-Martins</td>
<td>Brazil</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Integration of multimodal imaging and intraoperative MR in resective surgery for medically refractory epilepsy: The Erlangen experience of 415 patients</td>
<td>Karl Roessler</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quantitative analysis of intracranial EEG – relation to post-surgical seizure control in three patients with unfavorable outcome</td>
<td>Christian Rummel</td>
<td>Switzerland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prognostic predictors in non-selective amygdalohippocampectomy for refractory mesial temporal epilepsy</td>
<td>Alexandra Santos</td>
<td>Portugal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prediction of post-operative seizure-control using MRI, electric source imaging (ESI), ictal SPECT and PET</td>
<td>Margitta Seeck</td>
<td>Switzerland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recurrent seizures after anterior temporal lobectomy in patients with mesial temporal lobe epilepsy</td>
<td>Jong-Hwa Shin</td>
<td>Korea, Republic of</td>
</tr>
<tr>
<td>WEDNESDAY 14TH SEPTEMBER</td>
<td>BASIC SCIENCE 5</td>
<td>Using automated algorithms to analyze circadian changes of EEG biomarkers properties in patients with epilepsy</td>
<td>Jiri Balach</td>
<td>Czech Republic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identification of miRNA expression profiles in human mesial temporal lobe epilepsy with hippocampal sclerosis</td>
<td>Petra Bencurowa</td>
<td>Czech Republic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Blood-brain barrier markers after tonic-clonic seizures</td>
<td>Agnieszka Cudna</td>
<td>Poland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>High-frequency oscillation ability to localize epileptogenic tissue in animal epilepsy model</td>
<td>Tomas Havel</td>
<td>Czech Republic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Microseizures reliably localize primary epileptogenic areas in tetanus toxin model of temporal lobe epilepsy</td>
<td>Jan Kudlacek</td>
<td>Czech Republic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genome-wide microRNA expression profile and regulatory signaling pathways in Ganglioglioma</td>
<td>Atreye Majumdar</td>
<td>India</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cognitive deficits and brain myo-Inositol are early biomarkers of epileptogenesis in a rat model of epilepsy</td>
<td>Rosaria Pascente</td>
<td>Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Retrospective analysis of seizure-related heart rate change</td>
<td>Maryam Ravan</td>
<td>USA</td>
</tr>
</tbody>
</table>
**Wednesday 14th September**

**13:00 – 14:30 Basic Science 6**

**P159** N-palmitoylethanolamine enhances anticonvulsant effects of some antiepileptic drugs against audiogenic seizures in DBA/2 mice  
Rita Citraro, Italy

**P160** Absence crisis are susceptible to lamotrigine and ethosuximide in male taiep rats  
Carmen Cortes, Mexico

**P161** Effects of ketogenic diet on hippocampal calbindin-D28k expression in mice with kainic acid-induced seizures  
Dong Wook Kim, Korea, Republic of

**P162** Isobolographic analysis of interactions of lacosamide with selected antiepileptic drugs in three-drug combinations against maximal electroshock-induced seizures in mice  
Jarogniew Luszczki, Poland

**P163** ACR-Oil from natural source affects the kindling process in mice: analysis of molecular markers during epileptogenesis  
Saima Malhi, Pakistan

**P164** Dynamic S1P1 subunit expression patterns and in vivo EEG analysis suggest fingolimod as promising therapy option in focal epilepsies  
Julika Pitsch, Germany

**P165** Synergistic anticonvulsant effect between thalidomide and morphine on pentyleneetetrazole-induced clonic seizures in mice  
Nastaran Pourshadi, Iran, Islamic Republic of

**P166** How different subchronic supplementation regimens with folate and L-arginine affect EEG characteristics of homocysteine epilepsy?  
Aleksandra Rasic Markovic, Serbia

**P167** Acute post-status administration of endocannabinoid receptor agonist WIN-55,212-2 has a neuroprotective effect but does not prevent epileptogenesis  
Elena Suleymanova, Russian Federation

**P168** Inhibition of monoacylglycerol lipase (MAGL) by PF-4645 protects mice against refractory SE  
Gaetano Terrone, Italy

**P169** Optogenetic control of human neurons in hippocampal tissue cultures  
Jenny Wickham, Sweden

**Wednesday 14th September**

**13:00 – 14:30 Clinical Epilepsy 5**

**P204** Differences in quality of life of women and men with drug resistant epilepsy in Poland  
Aleksandra Bala, Poland

**P205** Educational video and story as effective interventions reducing epilepsy-related stigma among children measured by the verified Czech version of stigma scale of epilepsy  
Dana Brabcová, Czech Republic

**P206** Assessment of patients’ and caregiver’s perceived need to start actively participated outcome measures in epilepsy research  
Maria Grazia Celani, Italy

**P207** High rates of nicotine use and unemployment among pregnant women with epilepsy  
Anette Huuse Farmen, Norway

**P208** The added value of epilepsy experts in the emergency room after a first unprovoked seizure  
Lorraine Fisch, Switzerland

**P209** Do we avoid talking about sex?  
Oliver Henning, Norway

**P210** Validation of a German version of the Glasgow epilepsy outcome scale (GEOS) for people with epilepsy and intellectual disability  
Theodor May, Germany

**P211** Utilization of an anti-epileptic drug response database (ARD) in a multi-disciplinary clinic  
Viet-Huong Nguyen, USA

**P212** The DICES project (Driving Integrated Care in the Emergency room for Seizures)  
Jennifer Williams, Ireland
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30

CLINICAL EPILEPSY 6

P213  Modern portrait of a woman with epilepsy of childbearing age
       Diana Dmitrenko, Russian Federation

P214  What areas of lives of caregivers of children with severe, refractory
       epilepsy are affected by caregiving? An expert panel report
       Mark Jensen, USA

P215  Perceptions and preferences concerning the use of wearable sensors in
       epilepsy and Parkinson’s disease: a focus group study
       Dongni Johansson, Sweden

P216  Juvenile myoclonic epilepsy and driving licence: restrictions and
       medicolegal issues
       Nebojsa Jovic, Serbia

P217  Premarriage counselling by neurologist, improves marriage sustainability
       Chizuko Nagamori, Japan

P218  The knowledge and stigma for epilepsy in Japan

P219  A study of symptomatic epilepsy related to ischemic stroke
       Kei-Ichiro Takase, Japan

P220  Relation of perceived stigma to adverse events of medications in patients
       with epilepsy
       Ekaterina Viteva, Bulgaria

P221  Public awareness, understanding and attitudes toward epilepsy in
       Montenegro
       Slavica Vujisic, Montenegro

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30

CLINICAL NEUROPHYSIOLOGY 4

P252  Predictors of postictal generalized EEG suppression
       Betül Baykan, Turkey

P253  The effects of fixation-off sensitivity on eye closure and eye closed status-
       related epileptiform discharges
       Hava Ozlem Dede, Turkey

P254  Semiological features of secondary generalized tonic-clonic seizures with
       postictal generalized EEG suppression
       Kazutaka Jin, Japan

P255  The safety of augmented visual stimulation: Does repeated, extensive
       visual stimulation within a time-frame of one hour increase sensitivity in
       photosensitive patients?
       Dorothée Kasteleijn-Nolst Trenité, Italy

P256  The diagnostic accuracy of initial routine electroencephalography after a
       first transient loss of consciousness
       Milena Ković, Serbia

P257  Statistical learning methods for detection of generalized tonic-clonic
       seizures in accelerometer data
       Fredrik Ohlsson, Sweden

P258  Very high frequency oscillations in temporal lobe epilepsy
       Martin Pail, Czech Republic

P259  Time domain versus time-frequency domain as methods of analysis of
       single pulse electrical stimulation in patients with focal epilepsy
       Imogene K.G. Pieters, Netherlands

P260  TMS-EEG to measure anti-epileptic drug effect in the human brain
       Isabella Premoli, United Kingdom

P261  Zero-crossing interval analysis of EEG background rhythms – a new
       biomarker for epilepsy?
       Jan Pyrzowski, Poland
**WEDNESDAY 14TH SEPTEMBER**

**13:00 – 14:30**  
**EPILEPSY IN CHILDHOOD 10**

**P271**  
Photosensitive epilepsy and hot water epilepsy: an unusual combination  
Zeynep Aydin-Özemir, Turkey

**P272**  
Seizures as presenting and prominent symptom in chorea-acanthocytosis with c.2343del VPS13A gene mutation  
Felix Benninger, Israel

**P273**  
Plasma catecholamine levels in epileptic seizures  
Scott Bowman, USA

**P274**  
Transient Epileptic Amnesia – the acute anterograde amnesia chameleon  
Carlota Cunha, Portugal

**P275**  
Evaluation of sensitivity and properties of clinical variables in differentiation of seizure versus pseudoseizure  
Mehran Homam, Iran, Islamic Republic of

**P276**  
Faciobrachial dystonic seizures result from fronto-temporo-basalganglial network involvement  
Rajesh Iyer, India

**P277**  
MELAS in a young adult patient presenting with status epilepticus  
Demet Kinay, Turkey

**P278**  
Focal epilepsy leads to the emergence of a large-scale epileptic network that sustains the pathological state  
Laurent Sheybani, Switzerland

**P279**  
Phenotypes of juvenile myoclonic epilepsy amound patients in Siberia, Russia  
Olga Shilkina, Russian Federation

**WEDNESDAY 14TH SEPTEMBER**

**13:00 – 14:30**  
**EPILEPSY IN CHILDHOOD 11**

**P280**  
Living with Landau Kleffner syndrome  
Marte Årva, Norway

**P281**  
Early epileptic encephalopathies with suppression burst  
Prisca-Rolande Bassolé, Senegal

**P282**  
Typographic legibility and its phonological involvement in reading epilepsy  
Maria Graciela Cano Celestino, Mexico

**P283**  
Describing the humanistic burden of illness in Dravet syndrome – critical methodological questions remain  
John Irwin, United Kingdom

**P284**  
Drug resistant occipital epilepsy: Sturge-Weber variant or coeliac disease? A diagnostic dilemma  
Andreas Kiryttopoulos, Greece

**P285**  
Evolution of West syndrome in Georgia, predictors of outcome  
Ana Kvernadze, Georgia

**P286**  
EEF1A2 (eukaryotic elongation factor 1, alfa-2) related early infantile epileptic encephalopathy & myoclonic astatic epilepsy  
Ilan Linder, Israel

**P287**  
A novel description of a homozygous partial deletion of RBFOX1 gene causing epileptic encephalopathy, severe intellectual disability and progressive post-natal microcephaly  
Tally Lerman-Sagie, Israel

**P288**  
De novo KCNBL1 mutations cause infantile epileptic encephalopathy with generalized epileptiform discharges  
Jun Tohyama, Japan
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  EPILEPSY IN CHILDHOOD 12

P289  The use of NGS for the diagnosis of early onset epileptic encephalopathies: The clinical experience of an Italian centre
Ilaria Contaldo, Italy

P290  Clinical cases of successfully treated phenobarbital refractory seizures by use of combination of two antiepileptic drugs in preterm infants
Valentina Ivanovna Guzeva, Russian Federation

P291  Change of cytokine levels in neonatal seizures induced by hypoxic ischemic encephalopathy
In Goo Lee, Korea, Republic of

P292  Evaluation of etiology and prognostic factors of the developmental outcome in neonatal seizures
Bolyun Lee, Korea, Republic of

P293  Towards a composite clinical endpoint: identifying a core set of patient and caregiver relevant outcome measures through qualitative research on the global impact of Dravet syndrome
Rima Nabbout, France

P294  Optimization of treatment of pharmacological resistant forms of epilepsy in the case of epileptic encephalopathy
Komila Porsokhonova, Uzbekistan

P295  Management of seizures specifically in newborn hypoxic ischaemic encephalopathy (HIE) – review of the literature and results of a questionnaire on international practices- time for a fresh view?
Thorsten Villiers Stanley, New Zealand

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  EPILEPSY IN CHILDHOOD 9

P357  Clinical characteristics and ictal EEG findings of childhood and juvenile absence epilepsy in Algiers
Walid Abdellaooui, Algeria

P359  Benign familial and non-familial infantile seizures Fukuyama- Watanabe- Vigevano syndrome (F-W-V Syndrome) – two cases report
Sanja Delin, Croatia

P360  Clinical characteristics of Dravet syndrome and gene mutation analysis
Feng Gao, China

P361  A reaching/grasping movement by a patient with posttraumatic epilepsy
Toru Horinouchi, Japan

P362  The safety and efficacy of Perampanel among different groups of people with ID using the UK Anti-Epileptic Drug Intellectual Disability (Ep-ID) Register
Rohit Shankar, United Kingdom

P363  Clinical findings of tuberous sclerosis patients in Menderes region
Ayse Tosun, Turkey

P364  Diagnostic and management pitfalls in JME: hospital based study
Aleksandre Tsereteli, Georgia
**WEDNESDAY 14TH SEPTEMBER**

**13:00 – 14:30**  
**GENETICS 4**

- P391 Systematic recruitment and analysis of epilepsy families in Palestine  
  Amal Abu-Rayyn, Palestine

- P392 NTRK2, the TrkB gene, is associated with mood disorders in temporal lobe epilepsy  
  Marino Muxfeldt Bianchin, Brazil

- P393 Single nucleotide polymorphisms of antioxidant enzymes in progressive myoclonus epilepsy  
  Marko Ercegovac, Serbia

- P394 The phenotypic spectrum of the recurrent SCN2A R1319Q mutation  
  Ingo Helbig, Germany

- P395 PURA mutations: Intellectual disability with seizures or epileptic encephalopathy?  
  Helle Hjalgrim, Denmark

- P396 Targeted next generation sequencing as a diagnostic tool in 230 patients with epileptic encephalopathies  
  Line H. G. Larsen, Denmark

- P397 The phenotypic spectrum of a familial GRIN2A truncation mutation  
  Hiltrud Muhle, Germany

- P398 Systematic large scale genome-wide analysis of CNVs in patients with ‘epilepsy plus’  
  Hannah Stamberger, Belgium

- P399 Variable phenotypes in individuals with GRIN2A sequence variants or deletions  
  Danique R.M. Vlaskamp, Netherlands

- P400 SLC6A8 and BEWD3 genes mutations: intelectual disability vs normal IQ, macrocephaly and seizures  
  Hector Waisburg, Argentina

**13:00 – 14:30**  
**NEUROIMAGING 3**

- P421 Reversible MRI findings in a nonconvulsive status epilepticus patient with hyperammonemnic encephalopathy  
  Asli G. Akyol, Turkey

- P422 Predictors of cortical representation in patients with lesional epilepsy: an fMRI study  
  Carmen Barba, Italy

- P423 Reliability and reproducibility of single-voxel spectroscopy of the hippocampus in 1,342 consecutive studies of 670 patients with epilepsy  
  Tohru Hoshida, Japan

- P424 Reversible MRI abnormalities in patients presenting with epileptic seizures  
  Dimitrios Kazis, Greece

- P425 Reoision extent of the uncinate fasciculus and postoperative seizure outcome in temporal lobe epilepsy  
  Simon Keller, United Kingdom

- P426 Role of positron emission tomography (PET) of the brain in the diagnosis of epilepsy  
  Liudmila Lipatova, Russian Federation

- P427 Resting-state fMRI showed abnormal local spatiotemporal consistency in frontal lobe epilepsy  
  Cheng Luo, China

- P428 Peri-ictal changes on MRI neuroimaging  
  Joel Oster, USA

- P429 Prevalence and importance of the intracranial cysts in focal epilepsy patients: a tertiary referral center study  
  Aleksandar Ristic, Serbia

- P430 Postictal arterial spin labelling (ASL) MRI for the localization of seizure onset zone (SOZ): comparison with intracranial EEG-localization and postsurgical outcome  
  Shaily Singh, Canada

- P431 Postsurgical effects on functional connectivity within the limbic system in mesial temporal lobe epilepsy  
  Christian Weisstanner, Switzerland
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30

NEUROIMAGING 4

P432 Volume and shape analysis of thalamus in patients with newly diagnosed epilepsy
Batil Alonazi, United Kingdom

P433 The relationship between white matter abnormalities and cognitive functions in new-onset juvenile myoclonic epilepsies
Burcu Ekmekci, Turkey

P434 Source localization of ictal epileptic activity in patients with focal epilepsy validated with invasive EEG
Nino Epitashvili, Germany

P435 Thalamocortical microstructural abnormality in juvenile myoclonic epilepsy
Eman Esmail, Egypt

P436 The corticospinal tract in unilateral polymicrogyria – a multiparametric MRI study
Olivia Fösleitner, Austria

P437 Statistical cerebral blood flow mapping in patients with temporal lobe epilepsy
Barbara A. K. Kreilkamp, United Kingdom

P438 Social cognition in patients with juvenile myoclonic epilepsy: an fMRI study
Giorgi Kuchukhidze, Austria

P439 Visualisation of blood brain barrier impairment as early marker of post stroke epileptogenesis
Jakub Otáhal, Czech Republic

P440 Variable threshold in SPM analysis of ictal SPECT in epilepsy surgery patients
Vlastimil Sulc, Czech Republic

P441 Widefield imaging of seizure propagation through the visual cortex in an awake mouse
Robert Wykes, United Kingdom

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30

NEUROPSYCHOLOGY AND PSYCHIATRY IN EPILEPSY 3

P463 The rate of psychiatric comorbidity in psychogenic nonepileptic seizures compared with epilepsy in whom have demand for working disability for epilepsy
Kezban Aslan, Turkey

P464 Predicting the diagnosis of psychogenic non epileptic seizures and epileptic seizures by videorecording
Ettore Beghi, Italy

P465 Let’s do the induction of psychogenic seizures nonepileptic?
Ibrahim Bora, Turkey

P466 Importance of long term EEG/video monitoring in distinguishing psychogenic non-epileptic seizures from epileptic seizures
Susanne Davelaar, Netherlands

P467 Quality of life (QoL) and depression in patients during VEEG (2005-2014) – who suffers the most?
Anke M. Hermsen, Germany

P468 Interictal dysphoric disorder in patients with epilepsy
Maja Milovanovic, Serbia

P469 Suicidal risk factors in people with epilepsy
Nikolay G. Neznanov, Russian Federation

P470 Personality traits in patients with temporal lobe epilepsy
Annalisa Parente, Italy

P471 Should every child with epilepsy undergo screening for psychiatric comorbidities?
Shpresa Pula, UK, United Kingdom

P472 Should children with attention deficit/hyperactivity disorder (ADHD) and interictal epileptiform discharges (IEDs) on awake EEG be treated with antiepileptic drugs (AEDs) for their ADHD symptoms?
Dobrinko Socanski, Norway
WEDNESDAY 14th SEPTEMBER

13:00 – 14:30  OTHERS 6

P524 Limbic encephalitis: the intriguing link between autoimmune processes, epileptogenesis and neurodegeneration
Sara Casciato, Italy

P525 Improvement of interictal epileptiform discharges detection during EEG-fMRI: Pulse artefacts correction based on non-local means filtering
Giannina R. Iannotti, Switzerland

P526 Limbic Encephalitis: Early description in 1908
Günter Krämer, Switzerland

P527 Frequent rhabdomyolysis in anti-NMDA receptor encephalitis
Jung-Ah Lim, Korea, Republic of

P528 Interictal and postictal headache in our epilepsy patients
Tomáš Nežádal, Czech Republic

P529 Hippocampal involvement in physiological déjà vu: subfield vulnerability rather than temporal lobe epilepsy
Eva Pešlová, Czech Republic

P530 Iron, Vitamin B12, folic acid and vitamin D levels in febrile convulsions
F. Mujgan Sonmez, Turkey

P531 HLA-A, -B, -DRB1 haplotypic association with antiepileptic drugs induced cutaneous adverse drug reactions among patients from mainland of China
Xintong Wu, China

P532 Effect of seizures on sleep quality in patients with chronic epilepsy
Sung Sang Yoon, Korea, Republic of

P534 Retinal nerve fibre layer asymmetry associated with diagnosis of focal epilepsy in a drug-resistant population
Ana Paula Bartmann, United Kingdom

P535 Periictal changes of the innate immune system
Müjgan Doğan Önüşören, Germany

P536 Seizures in comatose CPR survivors treated with hypothermia
Anda Eilam, Israel

P537 Seizure prevention in angioplasty for symptomatic extracranial carotid and vertebral artery stenosis
Mohamed Elmahdy, Egypt

P538 Prag and epilepsy
Günter Krämer, Switzerland

P539 What are the opinions of patients with epilepsy and the families on counseling about SUDEP and other risks of epilepsy? The experience of the French sentinel network on epilepsy-related mortality
Marie-Christine Picot, France

P540 The relationship between rotavirus gastroenteritis and febrile convulsions
F. Mujgan Sonmez, Turkey
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30 PHARMACOLOGY/AEDS 10

P551 Behavioral disinhibition and GABAergic treatment in childhood epilepsy
Hilgo Bruining, Netherlands

P552 A prospective analysis of the effectiveness and tolerance of lacosamide in patients with refractory partial epilepsy
Ewa Czapinska-Ciepiela, Poland

P553 Adverse psychological effects of levetiracetam compared to seven other common anti-epileptic drugs in adults with epilepsy in general practice
Colin B. Josephson, Canada

P554 Adverse effects of dual anticonvulsant drug therapy in epilepsy patients – experience of a tertiary epilepsy outpatient clinic
Alexander Kowski, Germany

P555 Long-term safety and efficacy of adjunctive perampanel in patients with drug-resistant primary generalised tonic-clonic seizures in idiopathic generalised epilepsy: results of an open-label extension
Terence O’Brien, Australia

P556 Esi-Atlántico: an observational study on the use of Eslicarbazepine in North-West Spain
Gema Pérez-Lorenzo, Spain

P557 CBD-enriched medical cannabis for intractable pediatric epilepsy
Michal Tzadok, Israel

P558 Dried blood spots- a novel method for therapeutic drug monitoring in children with epilepsy in a homebased setting
Katarina Wide, Sweden

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30 PHARMACOLOGY/AEDS 11

P559 Flavonoids as potential reversing agents of the pharmacoresistance to antiepileptic drugs mediated by the P-glycoprotein
Ana Ferreira, Portugal

P560 Unraveling the role of blood-brain partitioning in the anticonvulsant and antiepileptogenic actions of lacosamide by in vitro pharmacokinetic studies
Zsolt Gáll, Romania

P561 A Phase 1 open-label crossover study to evaluate bioequivalence of oral suspension and tablet formulations of perampanel in healthy subjects
Antonio Laurenza, USA

P562 Eslicarbazepine acetate (ESL) and carotid intima-media thickness (cIMT) in males: The ESL-LIPID study
Pedro J. Serrano-Castro, Spain

P563 The impact of pharmacokinetic interactions with eslicarbazepine acetate versus oxcarbazepine and carbamazepine in clinical practice
Torleiv Svendsen, Norway

P564 Two-dimensional metal nanoparticle arrays towards quantifying carbamazepine in human plasma
Matteo Tommasini, Italy

P565 Ketogenic diet in refractory childhood epilepsy: introduction of an all liquid formulation in an outpatient setting
Amerins Weijenberg, Netherlands
P614 The ROME study (Retrospective Observational Multicenter study on ESL): 'efficacy and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy for adult patients with partial onset seizures and global effect on quality of life'
Giovanni Assenza, Italy

P615 Safety and tolerability of eslicarbazepine acetate as monotherapy in patients with newly diagnosed partial-onset seizures
Elinor Ben-Menachem, Sweden

P616 Reversible liver dysfunction associated with high dose ketamine in refractory status epilepticus
Hoe Chin Chua, Singapore

P617 Surveillance of the orphan drug rufinamide in Norway: patient and population aspects
André Gottås, Norway

P618 Retrospective study with perampanel in the Fjord District in Norway from 2013 up to February 2016. Patients diagnosed with POS and PGTC
Terje Kristensen, Norway

P619 Seizure freedom with perampanel treatment in patients with refractory epilepsy
Jukka Peltola, Finland

P620 The factors of pharmacoresistance of focal seizures, the efficacy of perampanel
Olga Rakhmanina, Russian Federation

P621 Safety and efficacy of zonisamide in refractory epilepsy patients: a retrospective study based on an early data
Songul Senadim, Turkey

P622 Use of rufinamide and other antiepileptic drugs in the management of adult patients (≥18 years) with Lennox–Gastaut syndrome
Christian Brandt, Germany

P623 Comparison of the serum cytokine levels before and after adrenocorticotropic hormone (ACTH) therapy in patients with infantile spasms
Ali Cansu, Turkey

P624 Addressing the challenges in conducting international European multicenter trials in rare diseases: Time for action?
Floor Jansen, Netherlands

P625 Transitioning patients from oxcarbazepine to eslicarbazepine acetate
Jussi Mäkinen, Finland

P626 Valproate induced severe hyperammonemonic encephalopathy successfully treated by carglumic acid in a child
Beata Rosdy, Hungary

P627 Time-to-seizure modeling of lacosamide monotherapy – impact of disease severity and other covariates on dropouts and seizure probability
Armel Stockis, Belgium

P628 Therapeutic drug monitoring of antiepileptic drugs and the correlation with seizure control
Supinya Tuntapakul, Thailand

P629 Efficacy and tolerability of perampanel in adolescent patients with generalized seizure types: a pooled analysis of six randomized studies
J Eric Piña-Garza, USA
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30 PROGNOSIS/EPIEMIOLOGY 3

P646 The clinical outcome of Lennox-Gastaut syndrome in adults
Güneş Altiokka Uzun, Turkey

P647 Long term prognostic role of EEG in juvenile myoclonic epilepsy
Vibeke Arnsten, Norway

P648 Clinical experiences in psychogenetic nonepileptic seizures between 2003 and 2016 explaining the diagnosis is the first and most important step of the treatment in clinical practice, and careful patient-doctor communication has a certain positive impact on patients’ seizure prognosis
Aylin Bican Demir, Turkey

P649 The surgery for drug-resistant epilepsy and quality of life
Irena Dolezalova, Czech Republic

P650 The results of the comparison of statistical data on epilepsy in Ukraine, obtained in different ways
Andriy Dubenko, Ukraine

P651 Clinical and etiological profiles of adult patients with post stroke seizures in Bishkek
Asel Jusupova, Kyrgyzstan

P652 Differences in long-term outcomes in patients with focal cortical dysplasia type IIb with and without somatic MTOR mutations
Takao Komatsubara, Japan

P653 Mortality in a cohort of 831 patients after noninvasive video-EEG telemetry
Dragoslav Sokies, Serbia

P654 The role of epilepsy surgery treatment in quality of life of the patient with refractory epilepsy experience from local outpatient care
Ariunjargal Togtokhjargal, Czech Republic

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30 STATUS EPILEPTICUS 3

P673 SESA syndrome with a novel EEG pattern
Asli G. Akyol, Turkey

P674 Status epilepticus in pediatric age: etiology, semiology and outcome in 173 children
Marcello Bellusci, Spain

P675 Sporadic case of Creutzfeld-Jacobs’s disease with EEG features of non-convulsive status epilepticus
Georgios Karafyles, Greece

P676 Topiramate for refractory nonconvulsive status epilepticus in elderly
Jooyong Kim, Korea, Republic of

P677 Seven cases of new onset refractory status epilepticus (NORSE) in Qatar: improved outcome with early immunotherapy
Gayane Melikyan, Qatar

P678 Reversible posterior leukoencephalopathy syndrome associated with nonconvulsive status epilepticus
Davorka Milat, Croatia

P679 Status epilepticus – can data from the past change our strategy today?
Iva Nachmilnerova, Czech Republic

P680 Refractory status epilepticus, are we refining treatment pathways?
Shanika Samarasekera, United Kingdom

P681 Short-term outcomes and major barriers in the management of convulsive status epilepticus in children
Teona Shatirishvili, Georgia

P682 StatNet EEG: an effective tool to diagnose non-convulsive status epilepticus after hours
Alexandra Voll, Canada
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  SURGICAL TREATMENT AND NEUROMODULATION 5

P720  The contemporaneous issues of the epilepsy surgery
Konstantin Abramov, Russian Federation

P721  SEEG and subdural electrodes: analyzing the trend of their use in a large Canadian Epilepsy Program
Jorge Burneo, Canada

P722  Stereo tubes technique: a novel substitute for intraoperative MRI in epilepsy surgeries
Nilesh Kurwale, India

P723  Surgical treatment of medically intractable temporal lobe epilepsy in prescul children
Magomed Mamathkanov, Russian Federation

P724  Temporal lobe epilepsy with not lateralizing scalp-EEG ictal onset underwent intracranial investigation: electroclinical findings and surgical outcome
Addolorata Mascia, Italy

P725  Temporal lobectomy for epilepsy: outcomes and surgical complications
Catherine Pringle, United Kingdom

P726  Seizure outcome two years after posterior quadrant resections 1990-2011 – prospective and population based data from the Swedish National Epilepsy Surgery Register
Bertil Rydenhag, Sweden

P727  Surgical treatment of drug-resistant forms of epilepsy
Igor Trifonov, Russian Federation

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  SURGICAL TREATMENT AND NEUROMODULATION 6

P728  Vagus nerve stimulation in children with focal epilepsy – 5 year follow up study
Eva Brichtova, Czech Republic

P729  Verbal learning and memory outcome in selective amygdalohippocampectomy versus temporal lobe resection in 108 patients with hippocampal sclerosis
Mette Thrane Foged, Denmark

P730  The Danish epilepsy surgery programme aligns with best international standards
Emil Holm, Denmark

P731  The implication of reduction of antiepileptic medication on postoperative outcome after epilepsy surgery
Ekaterina Pataraia, Austria

P732  Two-year and long-term seizure outcome after resective epilepsy surgery in patients with low IQ
Jesper Reinholdson, Sweden

P733  Three-dimensional visualization of morphometric brain anomalies in patients with temporal lobe epilepsy
Jakob Rosén, Sweden

P734  The role of regional epileptologist – can the estimated time of epilepsy onset to epilepsy surgery be effectively shortened?
Jana Slonková, Czech Republic

P735  Visual field defects in epilepsy patients treated with temporal lobe resection
Alvilda T. Steensberg, Denmark

P736  Trans-sylvian disconnection surgeries for medically intractable epilepsy including temporal lobe
Hidenori Sugano, Japan

P737  Utility of depth electrodes for epilepsy surgery and surgical outcome
Jae Hong Yi, Korea, Republic of
JOIN MORE THAN 6000 COLLEAGUES AT THE THIRD CONGRESS OF THE EUROPEAN ACADEMY OF NEUROLOGY!

www.ean.org/amsterdam2017
### TRAVEL BURSARIES

42 abstracts were selected for Travel Bursaries by the International Scientific and Organising Committee. The Travel Bursaries cover flights, accommodation and registration and are provided by the ILAE Commission on European Affairs.

The 12th ECE Travel Bursary recipients are:

<table>
<thead>
<tr>
<th>SURNAME</th>
<th>FIRST NAME</th>
<th>COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abi Warde</td>
<td>Marie</td>
<td>France</td>
</tr>
<tr>
<td>Bellucci</td>
<td>Marcello</td>
<td>Spain</td>
</tr>
<tr>
<td>Bibi</td>
<td>David</td>
<td>Israel</td>
</tr>
<tr>
<td>Blachut</td>
<td>Barbara</td>
<td>Germany</td>
</tr>
<tr>
<td>Bruno</td>
<td>Elisa</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Centeno</td>
<td>Maria</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Elissak</td>
<td>Martin</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>Elkjær</td>
<td>Lars Skou</td>
<td>Denmark</td>
</tr>
<tr>
<td>Ferrreira</td>
<td>Ana Filipa</td>
<td>Portugal</td>
</tr>
<tr>
<td>Galovic</td>
<td>Mariam</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Gnatkovsky</td>
<td>Vadym</td>
<td>Italy</td>
</tr>
<tr>
<td>Hernandez Ronquillo</td>
<td>Lizbeth</td>
<td>Canada</td>
</tr>
<tr>
<td>Huang</td>
<td>Cheng</td>
<td>China</td>
</tr>
<tr>
<td>Ilvento</td>
<td>Lucrezia</td>
<td>Italy</td>
</tr>
<tr>
<td>Kalina</td>
<td>Adam</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>Kaliss</td>
<td>Gudrun</td>
<td>Austria</td>
</tr>
<tr>
<td>Kapustina</td>
<td>Tatiana</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Kochetkova</td>
<td>Olga</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Lacuey Lembergier</td>
<td>Nurla</td>
<td>USA</td>
</tr>
<tr>
<td>Lagarde</td>
<td>Stanislas</td>
<td>France</td>
</tr>
<tr>
<td>Leal</td>
<td>Barbara</td>
<td>Portugal</td>
</tr>
<tr>
<td>Lichetta</td>
<td>Laura</td>
<td>Italy</td>
</tr>
<tr>
<td>Martinovic</td>
<td>Lukas</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>Matricardi</td>
<td>Sara</td>
<td>Italy</td>
</tr>
<tr>
<td>Mehta</td>
<td>Vinod Kumar</td>
<td>India</td>
</tr>
<tr>
<td>Menghi</td>
<td>Veronica</td>
<td>Italy</td>
</tr>
<tr>
<td>Mol</td>
<td>Arjen</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Pappalardo</td>
<td>Irene</td>
<td>Italy</td>
</tr>
<tr>
<td>Paul</td>
<td>Debasmita</td>
<td>India</td>
</tr>
<tr>
<td>Pieters</td>
<td>Imogene K.G.</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Roovers</td>
<td>Jolien</td>
<td>Belgium</td>
</tr>
<tr>
<td>Rossini</td>
<td>Laura</td>
<td>Italy</td>
</tr>
<tr>
<td>Sakuma</td>
<td>Satoru</td>
<td>Canada</td>
</tr>
<tr>
<td>Sezgin</td>
<td>Mine</td>
<td>Turkey</td>
</tr>
<tr>
<td>Sharma</td>
<td>Devina</td>
<td>India</td>
</tr>
<tr>
<td>Sveinsson</td>
<td>Olafur</td>
<td>Sweden</td>
</tr>
<tr>
<td>Trisiano</td>
<td>Marina</td>
<td>Italy</td>
</tr>
<tr>
<td>Umarov</td>
<td>Azamatjon</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>van der Lende</td>
<td>Marie</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Wickham</td>
<td>Jenny</td>
<td>Sweden</td>
</tr>
<tr>
<td>Wu</td>
<td>Xintong</td>
<td>China</td>
</tr>
<tr>
<td>Zerem</td>
<td>Ayelet</td>
<td>Israel</td>
</tr>
</tbody>
</table>

### SPEAKER AND CHAIR INDEX

<table>
<thead>
<tr>
<th>SURNAME</th>
<th>FIRST NAME</th>
<th>COUNTRY</th>
<th>SESSION TYPE</th>
<th>DATE</th>
<th>TIME</th>
<th>HALL</th>
<th>ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abi Warde</td>
<td>Marie</td>
<td>France</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ahl Mattilda</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Alomka Uzun</td>
<td>Gunes</td>
<td>Turkey</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Amirenova Jana</td>
<td>Czech Republic</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>South Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Apps Richard</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Aranca Eleonora</td>
<td>Netherlands</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>Aranca Eleonora</td>
<td>Netherlands</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Arzimanoglu Alexis</td>
<td>France</td>
<td>Special Symposium</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Arzimanoglu Alexis</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>Audnat Etienne</td>
<td>France</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Avrin Stéphane</td>
<td>France</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Avrin Stéphane</td>
<td>France</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Avrin Stéphane</td>
<td>France</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>Avrin Stéphane</td>
<td>France</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>South Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Avrin Stéphane</td>
<td>France</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Avoli Massimo</td>
<td>Canada</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Avoli Massimo</td>
<td>Canada</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Forum Hall</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>Avoli Massimo</td>
<td>Canada</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Baftiu Arton</td>
<td>Norway</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bagella Emilia</td>
<td>USA</td>
<td>Special Symposium</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bar-Klein Guy</td>
<td>Israel</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bartolomei Fabrice</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Basic Silvio</td>
<td>Croatia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Forum Hall</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>Basic Silvio</td>
<td>Croatia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Forum Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Baulac Michel</td>
<td>France</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christopher</td>
<td>Austria</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christopher</td>
<td>Austria</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christopher</td>
<td>Austria</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christopher</td>
<td>Austria</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christopher</td>
<td>Austria</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christopher</td>
<td>Austria</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baykun Betul</td>
<td>Turkey</td>
<td>Special Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Baykun Betul</td>
<td>Turkey</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>Beck Heinz</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>Becker Albert</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
<td></td>
</tr>
<tr>
<td>Becker Albert</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>--------------</td>
<td>--------------------</td>
<td>------------</td>
<td>---------------</td>
<td>------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Botter</td>
<td>Peter</td>
<td>Germany</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bigli</td>
<td>Eliott</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Bigli</td>
<td>Eliott</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bigli</td>
<td>Eliott</td>
<td>Italy</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bigli</td>
<td>Eliott</td>
<td>Italy</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Bigli</td>
<td>Eliott</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bencincini</td>
<td>Petra</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bencsely</td>
<td>Sandor</td>
<td>Denmark</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bencsely</td>
<td>Sandor</td>
<td>Denmark</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Bencsely</td>
<td>Sandor</td>
<td>Denmark</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bencsely</td>
<td>Sandor</td>
<td>Denmark</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bergin</td>
<td>Peter</td>
<td>New Zealand</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Bergin</td>
<td>Peter</td>
<td>New Zealand</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaker</td>
<td>Meir</td>
<td>Israel</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaker</td>
<td>Meir</td>
<td>Israel</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaker</td>
<td>Meir</td>
<td>Israel</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaker</td>
<td>Meir</td>
<td>Israel</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Blaker</td>
<td>Meir</td>
<td>Israel</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaker</td>
<td>Meir</td>
<td>Israel</td>
<td>Highlights Session</td>
<td>15-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Bibi</td>
<td>David</td>
<td>Israel</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bilen</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Bilen</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Brullic</td>
<td>Francesca</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bjellvik</td>
<td>Johan</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blumcke</td>
<td>Ingmar</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bliemertfeld</td>
<td>Hal</td>
<td>USA</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Boenewinkel-Wolf</td>
<td>Vanna</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Boon</td>
<td>Paul</td>
<td>Belgium</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Boon</td>
<td>Paul</td>
<td>Belgium</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Boon</td>
<td>Paul</td>
<td>Belgium</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Boon</td>
<td>Paul</td>
<td>Belgium</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Boris</td>
<td>Ieice</td>
<td>Switzerland</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Brandt</td>
<td>Christian</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Brandt</td>
<td>Christian</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Brandt</td>
<td>Claudia</td>
<td>Germany</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Beauon</td>
<td>Kees</td>
<td>Netherlands</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Beauon</td>
<td>Kees</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Brasildi</td>
<td>Milan</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>---------</td>
<td>--------------</td>
<td>------------</td>
<td>---------</td>
<td>----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>Neurobiology Sym.</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>Neurobiology Sym.</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>De Jonghe</td>
<td>Peter</td>
<td>Belgium</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Weerd</td>
<td>Al</td>
<td>Netherlands</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Weerd</td>
<td>Al</td>
<td>Netherlands</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Dedouweandre</td>
<td>Stefanie</td>
<td>Belgium</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Dedouweandre</td>
<td>Stefanie</td>
<td>Belgium</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall V</td>
<td>Chair</td>
</tr>
<tr>
<td>Dedouweandre</td>
<td>Stefanie</td>
<td>Belgium</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Delanty</td>
<td>Norman</td>
<td>Ireland</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Detofoli</td>
<td>Bertrand</td>
<td>France</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Devinsky</td>
<td>Oren</td>
<td>USA</td>
<td>Satellite Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Dimova</td>
<td>Petta</td>
<td>Bulgaria</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Dimova</td>
<td>Petta</td>
<td>Bulgaria</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Dixelišová</td>
<td>Irina</td>
<td>Czech Republic</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-10:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Donath</td>
<td>Vladimir</td>
<td>Slovakia</td>
<td>Special Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Doms</td>
<td>Laim</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Doms</td>
<td>Laim</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall V</td>
<td>Chair</td>
</tr>
<tr>
<td>Dudek</td>
<td>FE</td>
<td>USA</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Eisermann</td>
<td>Monika</td>
<td>France</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Eisermann</td>
<td>Monika</td>
<td>France</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ekolle nikole</td>
<td>Ekane</td>
<td>Finland</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elbakay</td>
<td>Sonia</td>
<td>Egypt</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Highlights Session</td>
<td>15-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elias</td>
<td>Martin</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elliger</td>
<td>Lars Skou</td>
<td>Denmark</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Finnell</td>
<td>Richard</td>
<td>USA</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>-----------</td>
<td>------------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>---------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Holbig</td>
<td>Kathrine</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Holbig</td>
<td>Inga</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Heltmaedter</td>
<td>Christoph</td>
<td>Norway</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Heltmaedter</td>
<td>Christoph</td>
<td>Norway</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Heltmaedter</td>
<td>Christoph</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Hershall</td>
<td>David</td>
<td>Ireland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Hershall</td>
<td>David</td>
<td>Ireland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Heuser</td>
<td>Kjell</td>
<td>Norway</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hinch</td>
<td>Edouard</td>
<td>France</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Holthausen</td>
<td>Hans</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Holthausen</td>
<td>Hans</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Holthausen</td>
<td>Hans</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Holtkamp</td>
<td>Martin</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>13-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Holtkamp</td>
<td>Martin</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>13-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Home</td>
<td>Robert</td>
<td>United Kingdom</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Huberfeld</td>
<td>Gilles</td>
<td>France</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Huberfeld</td>
<td>Gilles</td>
<td>France</td>
<td>Parallel Session</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Huishof</td>
<td>Hanna</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Irani</td>
<td>Sarosh</td>
<td>United Kingdom</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jędrzejczak</td>
<td>Joanna</td>
<td>Poland</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jacobs</td>
<td>Julia</td>
<td>Germany</td>
<td>Neurobiology Symp.</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jacobs</td>
<td>Julia</td>
<td>Germany</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jacobs</td>
<td>Julia</td>
<td>Germany</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jansen</td>
<td>Floor</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jansen</td>
<td>Floor</td>
<td>Netherlands</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jefferys</td>
<td>John</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jemmern</td>
<td>Poul</td>
<td>Denmark</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jesberger</td>
<td>Sebastian</td>
<td>Switzerland</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jina</td>
<td>Viktor</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jina</td>
<td>Viktor</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jirkova</td>
<td>Premysl</td>
<td>Czech Republic</td>
<td>Neurobiology Symp.</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jirkova</td>
<td>Premysl</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jobst</td>
<td>Barbara</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Johannesssen</td>
<td>Svein</td>
<td>Norway</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Johannesssen</td>
<td>Svein</td>
<td>Norway</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Johannesssen</td>
<td>Svein</td>
<td>Norway</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Johannesssen</td>
<td>Svein</td>
<td>Norway</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Johasssen</td>
<td>Cecilie</td>
<td>Norway</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>-----------</td>
<td>--------------------</td>
<td>------------</td>
<td>-----------</td>
<td>-------------</td>
<td>--------</td>
</tr>
<tr>
<td>Krikč</td>
<td>Vesna</td>
<td>Slovenia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Krsek</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Krsek</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kryšl</td>
<td>David</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kryšl</td>
<td>David</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Highlights Session</td>
<td>15-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kullmann</td>
<td>Dimitri</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kumlien</td>
<td>Eva</td>
<td>Sweden</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kumlien</td>
<td>Eva</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Labate</td>
<td>Angelo</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lagerbe</td>
<td>Leven</td>
<td>Belgium</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Lagerbe</td>
<td>Leven</td>
<td>Belgium</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lagerbe</td>
<td>Leven</td>
<td>Belgium</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lagerbe</td>
<td>Leven</td>
<td>Belgium</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lagerbe</td>
<td>Leven</td>
<td>Belgium</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lagardea</td>
<td>Stéphanie</td>
<td>France</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lee</td>
<td>Joo-Young</td>
<td>Korea, Republic of</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Lee</td>
<td>Yichten</td>
<td>Korea, Republic of</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lemke</td>
<td>Johannes</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Licchetta</td>
<td>Laura</td>
<td>Italy</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Linehan</td>
<td>Christine</td>
<td>Ireland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Linehan</td>
<td>Christine</td>
<td>Ireland</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Maguire</td>
<td>Melissa</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Maillard</td>
<td>Louis</td>
<td>France</td>
<td>ECE Forum</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Malmgren</td>
<td>Kristina</td>
<td>Sweden</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Malmgren</td>
<td>Kristina</td>
<td>Sweden</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Malmgren</td>
<td>Kristina</td>
<td>Sweden</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Malmgren</td>
<td>Kristina</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Mantegazza</td>
<td>Massimo</td>
<td>France</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mantegazza</td>
<td>Massimo</td>
<td>France</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Marchi</td>
<td>Nicola</td>
<td>USA</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Marchi</td>
<td>Nicola</td>
<td>USA</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Marchi</td>
<td>Nicola</td>
<td>USA</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Marchi</td>
<td>Nicola</td>
<td>USA</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Marchi</td>
<td>Nicola</td>
<td>USA</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Marchi</td>
<td>Nicola</td>
<td>USA</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>-----------</td>
<td>----------------</td>
<td>-----------</td>
<td>------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>O'Brien</td>
<td>Terence</td>
<td>Australia</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ødbø</td>
<td>Yva</td>
<td>Norway</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Ødbø</td>
<td>Yva</td>
<td>Norway</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Duas</td>
<td>Lea</td>
<td>France</td>
<td>ICE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Page</td>
<td>Rupert</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Paragotakai</td>
<td>Eleonora</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Penucca</td>
<td>Emilio</td>
<td>Italy</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Penucca</td>
<td>Emilio</td>
<td>Italy</td>
<td>ICE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Penucca</td>
<td>Emilio</td>
<td>Italy</td>
<td>ICE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Penucca</td>
<td>Emilio</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Pittau</td>
<td>Francesca</td>
<td>Switzerland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Pittau</td>
<td>Francesca</td>
<td>Switzerland</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Politzer</td>
<td>Tilman</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Preslier</td>
<td>René</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Puk</td>
<td>Oliver</td>
<td>Germany</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ramantani</td>
<td>Georgia</td>
<td>Germany</td>
<td>ICE Forum</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ravizza</td>
<td>Teresa</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ravizza</td>
<td>Teresa</td>
<td>Italy</td>
<td>ICE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ravizza</td>
<td>Teresa</td>
<td>Italy</td>
<td>ICE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Redfors</td>
<td>Petra</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>ICE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Reiner-Prinč</td>
<td>Zvonika</td>
<td>Slovenia</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rheims</td>
<td>Syksan</td>
<td>France</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rheims</td>
<td>Syksan</td>
<td>France</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Richardson</td>
<td>Mark</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Richardson</td>
<td>Mark</td>
<td>United Kingdom</td>
<td>ICE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Riddik</td>
<td>Leone</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Riley</td>
<td>Kate</td>
<td>Australia</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>------------------</td>
<td>------------</td>
<td>---------</td>
<td>-----------------------</td>
<td>-------</td>
<td>-----------</td>
<td>-------------</td>
<td>------------</td>
</tr>
<tr>
<td>Schulze-Bonhage</td>
<td>Andreas</td>
<td>Germany</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Schulze-Bonhage</td>
<td>Andreas</td>
<td>Germany</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>South Hall</td>
<td>13-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sen</td>
<td>Stefano</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sen</td>
<td>Stefano</td>
<td>United Kingdom</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Sematos</td>
<td>José</td>
<td>Spain</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shirozou</td>
<td>Hirosi</td>
<td>Japan</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shmuely</td>
<td>Sharon</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shuvor</td>
<td>Simon</td>
<td>United Kingdom</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shuvor</td>
<td>Simon</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shuvor</td>
<td>Simon</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Shuvor</td>
<td>Simon</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Simeji</td>
<td>Shhabana</td>
<td>Pakistan</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Simonato</td>
<td>Michele</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Skauup</td>
<td>Christian</td>
<td>Denmark</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-10:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Skauup</td>
<td>Christian</td>
<td>Denmark</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-10:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sumner</td>
<td>Björn</td>
<td>Germany</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Spek</td>
<td>Gunther</td>
<td>Austria</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sperring</td>
<td>Michael</td>
<td>USA</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Spreafico</td>
<td>Roberto</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Spreafico</td>
<td>Roberto</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Spreafico</td>
<td>Roberto</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Staley</td>
<td>Kevin J.</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Stefan</td>
<td>Hermann</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Steiger</td>
<td>Bettina</td>
<td>Switzerland</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Steiner</td>
<td>Emilia</td>
<td>Sweden</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Steinhauser</td>
<td>Christian</td>
<td>Germany</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Steinhäuser</td>
<td>Christian</td>
<td>Germany</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>---------</td>
<td>--------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>van Vliet</td>
<td>Erwin</td>
<td>Netherlands</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>van Vliet</td>
<td>Erwin</td>
<td>Netherlands</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vangoo</td>
<td>Vanshikha</td>
<td>Netherlands</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Varali-Kousaz</td>
<td>Ebna</td>
<td>Turkey</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Veensma</td>
<td>Tim</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Anna</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Anna</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Anna</td>
<td>Italy</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Anna</td>
<td>Italy</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vigoiano</td>
<td>Federico</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vigoiano</td>
<td>Federico</td>
<td>Italy</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vigoiano</td>
<td>Federico</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Vigoiano</td>
<td>Federico</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Villanueva</td>
<td>Vicente</td>
<td>Spain</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Villanueva</td>
<td>Vicente</td>
<td>Spain</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Villanueva</td>
<td>Vicente</td>
<td>Spain</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>van Podewils</td>
<td>Felix</td>
<td>Germany</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vonck</td>
<td>Krist</td>
<td>Belgium</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vonck</td>
<td>Krist</td>
<td>Belgium</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Vordenbulcke</td>
<td>Remi</td>
<td>Germany</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vrsi</td>
<td>Lubica</td>
<td>Slovenia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vuillemauz</td>
<td>Serge</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vuillemauz</td>
<td>Serge</td>
<td>Switzerland</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Waldman</td>
<td>Wytske</td>
<td>Netherlands</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Watiti Saadi</td>
<td>Nabe</td>
<td>Iraq</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Waldman</td>
<td>Jack</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Walker</td>
<td>Matthew</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Walker</td>
<td>Matthew</td>
<td>United Kingdom</td>
<td>Satellite Symposium</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Walker</td>
<td>Matthew</td>
<td>United Kingdom</td>
<td>Satellite Symposium</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Walker</td>
<td>Lauren</td>
<td>United Kingdom</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Walker</td>
<td>Matthew</td>
<td>United Kingdom</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wang</td>
<td>Xiaohan</td>
<td>China</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wedekynen</td>
<td>Sarah</td>
<td>Belgium</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Werhahn</td>
<td>Konrad</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Whalley</td>
<td>Ben</td>
<td>United Kingdom</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Welchelder</td>
<td>Franziska</td>
<td>Germany</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>West</td>
<td>Roland</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wrenell</td>
<td>Elaine</td>
<td>USA</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
</tbody>
</table>
EXHIBITION INFORMATION

EXHIBITION OPENING HOURS

Monday, September 12, 2016 09:00 – 16:30
Tuesday, September 13, 2016 09:00 – 16:30
Wednesday, September 14, 2016 09:00 – 16:30

EXHIBITION FLOOR PLAN

EXHIBITION STANDS

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Stand No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad-Tech Medical Instrument Corporation</td>
<td>1</td>
</tr>
<tr>
<td>AIT Austrian Institute of Technology</td>
<td>17</td>
</tr>
<tr>
<td>ALCIS NEURO</td>
<td>34</td>
</tr>
<tr>
<td>Amplexa Genetics</td>
<td>18</td>
</tr>
<tr>
<td>BIAL</td>
<td>10</td>
</tr>
<tr>
<td>BIOCODEX</td>
<td>31 &amp; 32</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>28</td>
</tr>
<tr>
<td>CeGaT GmbH</td>
<td>16</td>
</tr>
<tr>
<td>Compumedics Neuroscan</td>
<td>29</td>
</tr>
<tr>
<td>DEYMED Diagnostic</td>
<td>14 &amp; 15</td>
</tr>
<tr>
<td>EB NEURO SpA</td>
<td>2</td>
</tr>
<tr>
<td>Eisai</td>
<td>A</td>
</tr>
<tr>
<td>Electrical Geodesics, Inc.</td>
<td>7</td>
</tr>
<tr>
<td>ELEKTA</td>
<td>12 &amp; 13</td>
</tr>
<tr>
<td>Epilog</td>
<td>3</td>
</tr>
<tr>
<td>EpiNet</td>
<td>39</td>
</tr>
<tr>
<td>HOLBERG EEG</td>
<td>35</td>
</tr>
<tr>
<td>International Bureau for Epilepsy</td>
<td>23</td>
</tr>
<tr>
<td>International League Against Epilepsy</td>
<td>23</td>
</tr>
<tr>
<td>JOHN LIBBEY EUROTEXT</td>
<td>8</td>
</tr>
<tr>
<td>Lifelines iEEG</td>
<td>B</td>
</tr>
<tr>
<td>LivaNova</td>
<td>24 &amp; 25</td>
</tr>
<tr>
<td>Medtronic International Sàrl</td>
<td>33</td>
</tr>
<tr>
<td>Micromed</td>
<td>36</td>
</tr>
<tr>
<td>Natus Neurology Inc.</td>
<td>5</td>
</tr>
<tr>
<td>NIHON KOHDEN EUROPE GmbH</td>
<td>26 &amp; 27</td>
</tr>
<tr>
<td>Persyst Development Corporation</td>
<td>30</td>
</tr>
<tr>
<td>Shire</td>
<td>9</td>
</tr>
<tr>
<td>The Anita Kaufmann Foundation</td>
<td>39</td>
</tr>
<tr>
<td>UCB BIOPHARMA SPRL</td>
<td>11</td>
</tr>
<tr>
<td>WILEY</td>
<td>38</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>4</td>
</tr>
</tbody>
</table>
SPONSORS

The International League Against Epilepsy (ILAE) would like to acknowledge the support of the following companies for the 12th European Congress on Epileptology:

![Sponsors Logos](image)

These companies have provided funding towards the costs of the Congress, but have had no input into or influence over the programme schedule or content.

Sponsoring companies’ staff will be present at the Congress and sponsoring companies may have exhibition stands promoting their products.
Evaluating an investigational drug for Super-Refractory Status Epilepticus

The STATUS Trial is a Phase III study to evaluate the efficacy and safety of SAGE-547 Injection in the treatment of patients with Super-Refractory Status Epilepticus (SRSE).

For more information or to refer a patient, visit www.statustrial.com
Your Complete Neurology Solution from Compumedics

LONG TERM MONITORING LTM
BRAIN RESEARCH
AMBULATORY
SLEEP TESTING
ROUTINE CLINICAL EEG
LABORATORY BASED
CEEG FOR ICU
CLOUD SOLUTIONS
WIRELESS
FACILITY MANAGEMENT

INNOVATION. VALUE. VERSATILITY.

Explore Compumedics' comprehensive range of amplifiers and recorders for all your applications.

*GRAEL HD RANGE
*SIESTA WIRELESS
*SYNAMPS RESEARCH
*NEUVO LTM

Seamless and integrated software suite for diagnosis, data and facility management.

www.compumedics.com
Australia • USA • Germany • France

12TH ASIAN & OCEANIAN EPILEPSY CONGRESS
21ST - 24TH JUNE 2018

BALI
13th European Congress on Epileptology

26th - 30th August 2018

Vienna